Document:

Exhibit 10.8

 

EXCLUSIVE LICENSE AGREEMENT

 

Certain information in this document,
marked by brackets, has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933,
as amended, because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly
disclosed.

 

This
license agreement ("Agreement") is made effective this 1st day of December, 2011 ("Effective Date"),
by and between the Medical Research, Infrastructure, Health Services Fund of the Tel-Aviv Souraski Medical Center,
a not for profit corporation (Amuta) duly incorporated under the laws of the State of Israel with offices at 6 Weizmann Street.
Tel Aviv 64239, Israel (the "Fund"), of the one hand, and ChemomAb Ltd., a corporation dully incorporated under
the laws of the State of Israel having its registered office at 5 Azrieli Center Tel Aviv, c/o Horn &Co, Law Offices
("Licensee"), of the other hand.

 

Whereas:

 

A.         Certain
inventions, generally characterized as [***], including a patent application covering the foregoing and related know how and products
that have been developed by the Researchers (collectively "Invention"), solely in the course of research at the Tel
Aviv Medical Center ("TASMC"), by Prof. Jacob George and Prof. Gad Keren ("Researchers") and others and are
claimed in Patent Rights as defined below.

 

B.         Licensee
recognizes that the Researchers are/were employees of the FUND and assigned their rights
in and to the Invention to the FUND.

 

C.         The
Licensee wishes to obtain certain rights from the FUND for the commercial development of the Invention, in accordance with the
terms and conditions set forth herein and the FUND is willing to grant those rights so that the Invention may be developed and
the benefits enjoyed by the general public.

 

D.         Both
parties recognize and agree that Earned Royalties are due under this Agreement with respect to products, services and methods
and that such royalties will be paid with respect to both pending patent applications and issued patents, in accordance with the
terms and conditions set forth herein.

 

NOW, THEREFORE, in consideration
of the mutual promises set forth herein, and for good and valuable consideration the receipt and sufficiency of which are hereby
acknowledged, the parties agree as follows:

 

    

     

    

 

1. DEFINITIONS

 

As used in this Agreement,
the following terms, whether used in the singular or plural, shall have the following meanings:

 

1.1
 "Affiliate" of the Licensee means any entity which, directly or indirectly, Controls the Licensee, is
Controlled by the Licensee or is under common Control with the Licensee. "Control" means (i) having the
actual, present capacity to elect at least fifty percent (50%) of the directors of such affiliate; (ii) having the power
to direct at least fifty percent (50%) of the voting rights entitled to elect directors; or (iii) in any country where
the local law will not permit foreign equity participation of a majority, ownership or control, directly or indirectly, of
the maximum percentage of such outstanding stock or voting rights permitted by local law.

 

1.2"Attributed
Income" means the total gross proceeds including, without limitation, any license fees, maintenance fees, or milestone
payments), whether consisting of cash or any other forms of consideration and whether any rights other than Patent Rights are
granted, which gross proceeds are received by or payable to the Licensee and/or any Affiliate from any Sublicensee in consideration
of the grant of a sublicense or in connection with any agreement, arrangement or other relationship described in Paragraph 3 other
than Sublicensee Royalty or any Royalty received from an Affiliate and any amount in connection with an IPO or a Change of Control
Transaction (whether occurring prior to or after the receipt of an FDA approval). The foregoing shall exclude: any
amounts received in good faith and at the market price by Licensee and/or any Affiliate from any Sublicensee as reimbursement
of patent expenses and/or for the performance of new specific research and development work undertaken by any of the foregoing
at the request of the Sublicensee. For the avoidance of doubt, any gross proceeds meeting the definition set forth above in this
Article ‎1.2 shall be “Attributed Income” irrespective of whether such
gross proceeds are received under one or more separate agreements and irrespective of how such gross proceeds are referred to
or characterized by the Licensee or the Sublicensee.

 

1.3
 "Earned Royalty" means Sublicensee Royalty (as defined in Paragraph ‎6.1)
and Royalty (as defined in Paragraph ‎7.1)

 

1.4 "Know
How" means all inventions, developments and discoveries (whether patentable or not), designs, trade secrets,
proprietary information, know how, technology, technical data, research records, specifications and drawings, processes,
information, materials and all documentation and files embodying or evidencing any of the foregoing existing as of the date
hereof as a result of the research conducted at TASMC under the supervision of the Researchers in connection with the
Inventions.

 

1.5 "Licensed
Method" means any process, art or method the use or practice of which, but for the license granted in this
Agreement, would infringe, or contribute to, or induce the infringement of, any Patent Rights in any country were they issued
at the time of the infringing activity in that country.

 

    2

     

    

 

1.6 "Licensed
Product(s)" means any Product, including, without limitation, a Product for use or used in practicing a Licensed
Method and any Product made by practicing a Licensed Method, the manufacture, use, Sale, offer for Sale or import of which,
but for the license granted in this Agreement, would infringe, or contribute to, or induce the infringement of, any Patent
Rights in any country were they issued at the time of the infringing activity in that country including but not limited to
the construction of pro-drugs, and modified compounds based on the Patent Rights that work essentially in a physiologically
analogous manner to a Licensed Product.

 

1.7 "Licensed
Service" means any service provided for consideration (whether in cash or any other form), when such service
(i) involves the use of a Licensed Product; or (ii) involves the practice of a Licensed Method.

 

1.8 "Net
Invoice Price" means the gross invoice price charged and the value of any other consideration owed to the Licensee
and/or any Sublicensee for a Licensed Product or Licensed Service.

 

In any event the following items shall
be reduced, but only to the extent that they actually pertain to the disposition of such Licensed Product or Licensed Service,
are included in the gross invoice price charged or other consideration owed, and are identified separately on a bill or invoice:

 

1.8.1
[***];

 

1.8.2
[***];

 

1.8.3[***].

 

1.8.4
[***];

 

1.8.5 [***];
and

 

1.8.6 [***].

 

1.9 "Net
Sale" means except in the instances described in Paragraphs ‎1.9.1, ‎1.9.2,
and ‎1.9.3 of this Paragraph, the Net Invoice Price:

 

1.9.1
for any Relationship-Influenced Sale of a Licensed Product or Licensed Service, Net Sales shall be based on the Net Invoice
Price at which the Relationship-Influenced Sale Purchaser re-Sells such Licensed Product or Licensed Service

 

1.9.2
in those instances where Licensed Product or Licensed Service is not Sold, but is otherwise exploited, the Net Sales for such
Licensed Product or Licensed Service shall be the Net Invoice Price of products or services of the same or similar kind and
quality, Sold in similar quantities, currently being offered for Sale by the Licensee and/or any Sublicensee.

 

    3

     

    

 

1.9.3
for transfers or dispositions of Licensed Product or Licensed Service for no consideration or for consideration at or below
the manufacturing cost thereof in commercially reasonable quantities for charitable (i.e., for use in an investigator
initiated study by a not-for profit entity or for compassionate use purposes) or promotional purposes or for pre-clinical,
clinical, manufacturing scale-up, regulatory, governmental (i.e., required by a governmental authority to be supplied
to a governmental authority for use by such governmental authority) or for further research and development (i.e.,
quality assurance, quality control, compound assays, or similar activities, whether conducted pre-and/or post-approval)
purposes shall not be included in the calculation of Net Invoice Price or Net Sales.

 

1.10 "New
Developments" means inventions, or claims to inventions, which constitute advancements, developments or improvements,
whether or not patentable and whether or not the subject of any patent application, whether or not sufficiently supported by the
specification of a previously-filed patent or patent application within the Patent Rights to be entitled to the priority date
of the previously-filed patent or patent application and whether or not the subject of any patent or patent application, respectively
created or filed subsequent to the Effective Date, by Licensee or researchers of the Licensee, all within the field of the Invention.

 

1.11 "Patent
Prosecution Costs" is defined in Paragraph ‎19.4.

 

1.12

 

"Patent Rights" means
the Valid Claims of, to the extent assigned to or otherwise obtained by the FUND, the patents and patent applications specified
in Appendix B.

 

Patent Rights shall further include the
Valid Claims of, to the extent assigned to or otherwise obtained by the FUND, the corresponding foreign patents and patent applications
(requested under Paragraphs 19.5 and 19.6 herein) and any reissues, extensions, substitutions, continuations, divisions, continuation-in-part
applications.

 

1.13
 "Product" means any kit, article of manufacture, composition of matter, material, compound, component or
product.

 

1.14
 "Related Party" means a corporation, firm or other entity with which, or individual with whom, the Licensee
or any Sublicensee (or any of its respective stockholders, subsidiaries or Affiliates) have any agreement, understanding or
arrangement (for example, but not by way of limitation, an option to purchase stock or other equity interest, or an
arrangement involving a division of revenue, profits, discounts, rebates or allowances) unrelated to the Sale or exploitation
of the Licensed Products or Licensed Services (the “Other Agreement”): (i) if without the Other Agreement,
the amounts, if any, charged by the Licensee or Sublicensee to such entity or individual for the Licensed Product or Licensed
Service, would have been higher than the Net Invoice Price actually received, or (ii) if the Other Agreement results in
the Licensee, or Sublicensee extending to the counter party prices for such Licensed Product or Licensed Service that are
lower than those charged to others buying similar products or services in similar quantities and are not parties to similar
agreement, understanding or arrangement.

 

    4

     

    

 

1.15 "Relationship-Influenced
Sale" means a Sale of a Licensed Product or Licensed Service, or any exploitation of the Licensed Product or
Licensed Method, between the Licensee and/or any Sublicensee and/or (i) an Affiliate; (ii) a Related Party or
(iii) the Licensee or a Sublicensee

 

1.16
 "Sale" means the act of selling, leasing or otherwise transferring, providing, or furnishing for use for any
consideration. Correspondingly, "Sell" means to make or cause to be made a Sale and "Sold" means to have
made or caused to be made a Sale.

 

1.17
 "Sublicensee" means any person or entity (including any Affiliate) to which any of the license rights
granted to the Licensee hereunder are sublicensed.

 

1.18 "Sublicense
Fee" is defined in Paragraph ‎6.1.

 

1.19"Valid
Claim" means a claim of a patent or patent application in any country that (i) has not expired; (ii) has not
been disclaimed; (iii) has not been cancelled or superseded, or if cancelled or superseded, has been reinstated; and (iv) has
not been revoked, held invalid, or otherwise declared unenforceable or not allowable by a tribunal or patent authority of competent
jurisdiction over such claim in such country from which no further appeal has or may be taken.

 

2. GRANT

 

2.1 License.
Subject to the limitations and other terms and conditions set forth in this Agreement and subject to the Licensee fulfilling
its undertakings and obligations herein, the FUND grants to the Licensee a license in and to Patent Rights and the Know How to
research, develop, make, use, market, Sell, offer for Sale and import Licensed Products and Licensed Services and to practice
Licensed Methods, in all other countries where the FUND may lawfully grant such licenses, and for all applications and form of
use, provided however that the that same terms and conditions as set forth herein apply for each and every application.

 

2.2 Exclusive. Except
as otherwise provided for in this Agreement, the license granted in Paragraph ‎2.1 is exclusive.

 

2.3
Reserved Rights. The FUND and TASMC reserve and retain the right (and the
rights granted to the Licensee in this Agreement shall be limited accordingly) to make, use and practice the Invention and
any technology relating to the Invention (and to grant any of the foregoing rights to other educational and non-profit
institutions) for its own internal non commercial educational and research purposes only, including without limitation,
research sponsored by commercial entities (subject to the foregoing limitations) and including publication and other
communication of any research results (subject to the preservation of the confidential nature of the Inventions and
accordingly any disclosure which may prejudice such confidential nature will require prior consent of Licensee). Nothing
contained herein shall be deemed to provide the FUND and TASMC the right to grant to any commercial entity rights to the
Patent Rights or the Know How for as long is this Agreement is in effect. For the avoidance of doubt, to the extent the
Invention and any technology relating to the Invention are not the subject of the exclusive license granted to the Licensee
hereunder, the FUND and TASMC shall be free to make, use, Sell, offer to Sell, import, practice and otherwise commercialize
and exploit (including to transfer, license to, or have exercised by, third parties) for any purpose whatsoever and in its
sole discretion, such Invention, technology and any Products or processes that are the subject of any of the
foregoing.

 

    5

     

    

 

2.4 Technology
Transfer and Further Assistance

 

Immediately following the Effective Date,
at a time requested by Licensee and reasonably acceptable to the FUND, the FUND will transfer to Licensee the information and
materials specified in Exhibit 2.4A hereto and any other Know How identified at the Effective Date as being needed or reasonably
useful for Licensee to exploit the license granted hereunder. The FUND will use its best efforts to provide the materials in an
orderly manner and not contaminated.

 

In addition, in the event that at any
time following the Effective Date and prior to the closing of the Funding (as defined below), Licensee requires the assistance
of the FUND in connection with the activities specified in Exhibit 2.4B, the FUND will use its best efforts to provide Licensee
with the relevant resources (administration, research services, materials and access to laboratories) on a timely and professional
manner. Payment to the FUND for consumables and researchers time according to out of pocket costs borne by the FUND and otherwise
in accordance with its standard rate upon and subject to the closing of the Funding.

 

3. SUBLICENSES

 

3.1
Licensee’s Right to Grant Sublicenses. The FUND also grants to the Licensee the right to sublicense
to third parties (including to Affiliates) the rights granted to the Licensee hereunder, with the right to further sublicense
as provided below, as long as the Licensee has current exclusive rights thereto under this Agreement. Each Sublicensee must
be subject to a written sublicense agreement. All sublicenses will include all of the rights of, and will require the
performance of all the obligations due to, the FUND (and, if applicable, the Israeli Government and other sponsors), other
than those rights and obligations specified in Paragraphs ‎19.4 and ‎19.7 (reimbursement of Patent Prosecution
Costs). A Sublicensee shall be entitled to further sublicense the rights granted to it by Licensee provided that (i) the
additional Sublicensee assumes the rights and obligations of the original Sublicensee; and (ii) the prior approval of
the Fund is received provided that the approval shall not be unreasonably withheld. The Licensee shall notify the FUND of the
foregoing and the Fund shall provide its response within 20 days following receipt of the request. If response is not
received within the foregoing 20 days then the request shall be deemed approved. Any disapproval shall be provided together
with the reasons for the disapproval and the disapproval shall not be deemed to be made on reasonable grounds (unless
specifically otherwise demonstrated by the Fund) if the additional Sublicensee is a publicly traded company in a reputable
public market. Also, for the avoidance of doubt, Affiliates shall have no licenses under this Agreement unless such
Affiliates are granted a sublicense and shall be entitled to further sublicense any of the rights granted to it by the
Licensee under terms similar to which the Licensee shall be entitled to sublicense such rights. For the purposes of this
Agreement, the operations of all Sublicensees shall be deemed to be the operations of the Licensee, for which the Licensee
shall be responsible.

 

    6

     

    

 

3.2 Sublicense
Agreements. The Licensee will notify the FUND of each sublicense granted hereunder and will provide the FUND with a
complete copy of each sublicense and each amendment to such sublicense within thirty (30) days of issuance of such sublicense
or such amendment. Any sublicense by a Sublicensee or an extract of its material terms will be provided to the FUND prior to
its execution for review and exercise of rights as set forth in Section 3.1. The Licensee will collect from Sublicensees
and pay to the FUND all fees, payments, royalties and the cash equivalent of any consideration due the FUND and shall remain
responsible to such payment as indicated above. The Licensee will require Sublicensees to provide it with copies of all
progress reports and royalty reports in accordance with the provisions herein and the Licensee will collect and deliver all
such reports due the FUND from Sublicensees.

 

3.3 Termination. Upon
any expiration or termination of this Agreement for any reason, all sublicenses shall automatically terminate, unless the
FUND, at its sole discretion, agrees in writing to an assignment to the FUND of any sublicense. In the event of termination
of this Agreement, the FUND to favorably consider acceptance of the assignment of any sublicense, provided that the FUND will
not be bound by any grant of rights broader than or will not be required to perform any obligation other than those rights
and obligations contained in this Agreement. Moreover, the FUND will have the sole right to modify each such assigned
sublicense to include all of the rights of the FUND (and, if applicable, the Israeli Government and other sponsors) that are
contained in this Agreement, including the payment of Earned Royalties directly to the FUND by the Sublicensee as if it were
the Licensee at a rate that is no lower than the rate set forth in Article ‎7 (Earned Royalties) in accordance with
Article ‎5 (Payment Terms).

 

4 UNUSED
TECHNOLOGY

 

4.1 SUBLICENSING
Unused Technology. If at any time following the tenth (10) year anniversary of the Effective Date, a third party
desires to obtain a license under any of Patent Rights then the FUND shall have the right to give notice to Licensee of the
third party's desire to obtain a license. Within sixty (60) days after receipt of such notice, Licensee shall give notice to
the FUND whether such rights are not then being exercised and there is no plan to exercise such rights by Licensee, an
Affiliate, and/or Sublicensee of Licensee in the course of developing, making, having made, using, selling, offering for sale
or importing a Licensed Product and/or developing, using, selling or offering for sale a Licensed Method covered by Patent
Rights (an “Unused Technology”).

 

    7

     

    

 

4.2 Due
Diligence.  If Licensee gives notice to the FUND that it intends to use the Unused Technology, the parties will amend
Paragraph ‎9.3, as applicable, to include a provision for the time frame to commence
using the Unused Technology and specifying milestones therefore, and a failure by Licensee to use the Unused Technology
within such time or to meet such milestones will be subject to the provisions of Paragraph ‎9.5
and Article ‎13.

 

4.3 Third
Party Offer. In the event that Licensee elects not to develop Unused Technology, Licensee may notify the FUND, within thirty
(30) days of receipt of notification from the FUND pursuant to Paragraph ‎4.1 above, of its
intent to sublicense such Patent Rights for commercialization of Unused Technology. The FUND, upon receipt of such
notification, shall refer such third party to Licensee so that such third party may request a sublicense allowing for the
commercialization of the Unused Technology. Licensee agrees to negotiate in good faith the terms of a sublicense under
reasonable terms with such third party. If Licensee does not grant a sublicense to such third party within one hundred and
eighty (180) days (or any additional time period that may be agreed to in writing by the FUND), or refuses to grant such
sublicense under reasonable terms, then Licensee shall promptly, or, in the event of such refusal, within thirty (30) days
after such refusal, submit to the FUND a report specifying the license terms proposed by the third party.

 

5. PAYMENT
TERMS

 

5.1 Definitions. Paragraphs
 ‎1.4, ‎1.6, ‎1.7 and ‎1.12 define Licensed Method, Licensed Product, Licensed Service and Patent Rights, so
that Earned Royalties are payable on products and methods covered by both pending patent applications and issued patents.
Earned Royalties will accrue in each country for the duration of Patent Rights in that country and will be payable to the
FUND when Licensed Products or Licensed Services are invoiced in a manner constituting a Net Sale as defined in Paragraph
 ‎1.9 and in accordance with Section 5.2 below. Sublicense Fees with respect to any Attributed Income shall accrue to
the FUND within thirty (30) days of the date that such Attributed Income is received by the Licensee.

 

5.2 Quarterly
Payment Schedule. The Licensee will pay to the FUND all Earned Royalties, Sublicensee Royalties and other
consideration payable to the FUND (other than Sublicense Fees which is covered under Paragraph 5.1 above) quarterly on or
before February 28 (for the calendar quarter ending December 31), May 31 (for the calendar quarter ending
March 31), August 31 (for the calendar quarter ending June 30) and November 30 (for the calendar quarter
ending September 30) of each calendar year. Each payment will be for Earned Royalties, Sublicensee Royalties and other
consideration which has accrued within the Licensee's most recently completed calendar quarter.

 

    8

     

    

 

5.3
Payments. All consideration due the FUND will be payable and will be made in United States dollars by
check payable to the FUND or by wire transfer to an account designated by the FUND. The Licensee is responsible for all bank
or other transfer charges. When Licensed Products or Licensed Services are Sold for monies other than United States dollars,
the Earned Royalties and other consideration will first be determined in the foreign currency of the country in which such
Licensed Products or Licensed Services were Sold and then converted into equivalent United States dollars. The exchange rate
will be the average exchange rate quoted in the The Wall Street Journal during the last thirty (30) days of the
applicable payment period.

 

5.4 Taxes. If
applicable laws require that taxes be withheld from any amounts due to the FUND hereunder, Licensee shall (a) deduct
these taxes from the remittable amount, (b) pay the taxes to the proper taxing authority, and (c) promptly deliver
to the FUND a statement including the amount of tax withheld and justification therefor, and such other information as may be
necessary for tax credit purposes.

 

5.5 Foreign
Currency. Notwithstanding the provisions of Article ‎26 (Force Majeure)
if at any time legal restrictions prevent the prompt remittance of Earned Royalties or other consideration owed to the FUND
by the Licensee in USD, Licensee shall pay any amounts due to the
FUND through whatever lawful methods the FUND reasonably designates; provided, however, that if the FUND fails to designate
such payment method within thirty (30) days after the FUND is notified of the restriction, Licensee may deposit such payment
in local currency to the credit of the FUND in a recognized banking institution selected by Licensee and identified by
written notice to the FUND, and such deposit shall fulfill all obligations of Licensee to the FUND with respect to such
payment.

 

5.6 Late
Payment Charge. In the event that royalties, fees, reimbursements for Patent Prosecution Costs or other monies owed
to the FUND are not received by The FUND when due, the Licensee will pay to the FUND interest at a rate of LIBOR + 2% per
annum. Such interest will be calculated from the date payment was due until actually received by the FUND. Such accrual of
interest will be in addition to and not in lieu of, enforcement of any other rights of the FUND due to such late payment. The
LIBOR rate will be the average LIBOR rate quoted in the Financial Times during the last thirty (30) days prior to the date
payment was actually received by the FUND.

 

6. PAYMENTS
ON SUBLICENSES

 

6.1
Attributed Income. The Licensee will pay to the FUND a non-refundable and non-creditable sublicense fees
("Sublicense Fees") Ten percent (10%) of all Attributed Income.

 

    9

     

    

 

6.2 Royalty
on Sales by Sublicensee. (i) [***] ([***]%) of the Net Sales or Service Income by the Sublicensee; and
(ii) [***] ([***]%) of the Net Sales or Service Income by the Sublicensee exceeding [***] (U.S. $[***]) per [***]
("Sublicensee Royalty").

 

7. EARNED
ROYALTIES

 

7.1 Royalty
on Sales By Licensee and Affiliates. The Licensee will also pay to the FUND an earned royalty of
(i) [***] ([***]%) of the Net Sales or Service Income by the Licensee or any Affiliate; and (ii) [***]
([***]%) of the Net Sales or Service Income by the Licensee or any Affiliate exceeding [***] (U.S. $[***]) per [***]
("Royalty"). In the event in which any of the Licensed Products are sold as combined with "a new
ingredient", the Parties shall meet for purposes of negotiating its implications on payments of royalties on sales and
all other consideration due and payable to FUND.

 

8. MILESTONE
PAYMENTS

 

8.1 Milestone
Events and Amounts. With respect to each Licensed Product, the Licensee will pay to the FUND the following
non-refundable, non-creditable amounts:

 

8.1.1
One hundred thousand dollars (U.S. $100,000) upon submission of a New Drug Application (“NDA”), Biological
License Application (“BLA”) or equivalent for each Licensed Product to the United States Food and Drug
Administration (“FDA”), one hundred thousand dollars (U.S. $100,000) upon submission of similar application for
each Licensed Product to an equivalent foreign regulatory agency in Europe and one hundred thousand dollars (U.S. $100,000)
upon submission of similar application for each Licensed Product to an equivalent foreign regulatory agency in Asia. Payment
in the aggregate shall not be more than US$300,000 per each Licensed Product, provided however that for each jurisdiction,
payment shall be made only once; and

 

8.1.2
Two hundred thousand dollars (U.S. $200,000) upon the grant of FDA or equivalent agency marketing approval in Europe and/or
Asia for each Licensed Product. Payment in the aggregate shall not be more than US$600,000 per each Licensed Product,
provided however that for each jurisdiction, payment shall be made only once.

 

8.2 Timing. The
milestone payments of Paragraph ‎8.1 are due to the FUND within thirty (30) days after the occurrence of the applicable
milestone event.

 

8.3 Exit
Fee. In addition to the payments of Paragraph ‎8.1, within sixty (60) days after the first to occur of
either:

 

		(i)	closing of a public offering of the
                                         ordinary shares of Licensee pursuant to a registration statement filed with the Securities
                                         and Exchange Commission; or

 

		(ii)	a Change of Control Transaction,

 

    10

     

    

 

Licensee shall make
to the FUND a cash payment equal to 1% of the proceeds raised by the Company in its initial public offering or 1% of the consideration
received by the Company or its shareholders at the closing of a Change of Control Transaction (after deduction of any amount paid
to the shareholders of the Company as liquidation preference on account of their investment in the Company, if any), but in any
event not more than Three Million Dollars (U.S. $3,000,000). Upon the closing of an IPO, the FUND shall be entitled to waive its
right to receive payment hereunder in connection therewith and payment shall be made after the first to occur of any subsequent
Change of Control Transaction.

 

As used herein, a
 "Change of Control Transaction" means any consolidation, merger, reorganization or other transaction or series of transactions,
in which greater than thirty five percent (35%) of the voting power or the capacity to elect at least thirty five percent (35%)
of the directors of Licensee is transferred or issued to a third party taking place following receipt of FDA approval. Any similar
transaction occurring prior to receipt of FDA approval shall not be deemed Change of Control for the purpose hereof.

 

9. DUE
DILIGENCE

 

9.1
General. The Licensee, upon execution of this Agreement, will diligently proceed with the development,
manufacture and Sale of Licensed Products and Licensed Services.

 

9.2 Regulatory
Approvals. The Licensee will be responsible and use its best efforts to obtain all necessary governmental approvals
in each country where Licensed Products and Licensed Services are manufactured, used, Sold, offered for Sale or
imported.

 

9.3 Specific
Achievements. The Licensee will:

 

9.3.1 file
an Investigational New Drug Application (“IND”) or equivalent covering a Licensed Product with the FDA or
equivalent foreign regulatory agency within [***] months after the Effective Date;

 

9.3.2 initiate
Phase I clinical trials for a Licensed Product within [***] months after the Effective Date

 

9.3.3  market
Licensed Product in the United States within [***] months of receiving approval of such Licensed Product from the FDA; and use
reasonable commercial efforts to fill the market demand for Licensed Products and Licensed Services following commencement of
marketing at any time during the exclusive period of this Agreement. Nothing contained herein shall be construed or interpreted
as a basis for termination of this Agreement if FDA approval is not obtained and no assurances are made that such approval is
obtained.

 

9.4  Defaults.
If the Licensee is unable to perform any of the above provisions and is not at the time investing significant efforts in meeting
the applicable provision, then the FUND has the right and option to either terminate this Agreement or reduce the exclusive license
granted to the Licensee to a nonexclusive license in accordance with Paragraph ‎9.8 below.
This right, if exercised by the FUND, supersedes the rights granted in Article ‎2
(Grant).

 

    11

     

    

 

9.5 Equity
Funding. In addition to the obligations set forth above in Paragraph ‎9.3,
Licensee shall raise a minimum of [***] ($[***]) in first round funding, equity, and/or collaborative research funding within
twelve (12) months after the Effective Date (the “Funding”).

 

9.6 Default-Financial. If
the Licensee fails or is unable to comply with the funding and spending requirements set forth in Paragraph ‎9.5,
then the FUND has the right and option to either terminate this Agreement or reduce the exclusive license granted to the
Licensee to a nonexclusive license, subject to Paragraph ‎9.8. This right, if
exercised by the FUND, supersedes the rights granted in Article ‎2
(Grant).

 

9.7 Default-Regulatory. The
FUND recognizes that, taking into account the uncertainties of scientific research and development, the nascent state of the
technology licensed under this Agreement, and the need for considerable further research and development of the technology
before it will be possible to commercialize a Licensed Product, it may be necessary from time to time to amend the milestones
of Paragraphs ‎9.3.1 through 9.3.3. Accordingly, the FUND hereby agrees to
consider in good faith any reasonable proposals from Licensee to amend the milestones of Paragraphs ‎9.3.1
through 9.3.3 in light of Licensee's experience in implementing the development of the Licensed Products under this
Agreement, and the FUND and Licensee agree to negotiate in good faith for a period of ninety (90) days as may be appropriate
to carry out the purposes and intent of this Agreement if despite diligent effort by Licensee, by a date specified in
Paragraphs ‎9.3.1 through 9.3.3, Licensee is unable to meet the specified
milestone. If, however, notwithstanding good faith negotiation, the parties are unable to agree upon any modification to this
Agreement, then the parties will be under no further obligation to negotiate, and the Agreement's terms shall
govern.

 

9.8 Cure
Period. To exercise either the right to terminate this Agreement or to reduce the exclusive license granted to the
Licensee to a non-exclusive license for lack of diligence required in this Article ‎9
(Due Diligence), the FUND will give the Licensee written notice, specifying in reasonable detail the nature of the
deficiency. The Licensee thereafter has sixty (60) days to cure such deficiency. If the FUND has not received written
tangible evidence satisfactory to the FUND that the deficiency has been cured by the end of the sixty (60)-day period, then
the FUND may, at its option, terminate this Agreement immediately without the obligation to provide sixty (60) days' notice
as set forth in Article ‎13 (Termination by the FUND) or reduce the exclusive
license granted to the Licensee to a non-exclusive license by giving written notice to the Licensee.

 

    12

     

    

 

10. PROGRESS
AND ROYALTY REPORTS

 

10.1 Annual
Reports. Beginning on January 1, 2012, and annually thereafter, the Licensee will submit to the FUND a written
progress report as described in Paragraph ‎10.2 below covering the Licensee's (and any Affiliates', or Sublicensee's)
activities related to the development and testing of all Licensed Products and Licensed Services and related to the obtaining
of the governmental approvals necessary for marketing and the activities required and undertaken in order to meet the
diligence requirements set forth in Article ‎9 (Due Diligence). Progress reports are required for each Licensed
Product and Licensed Service until the first Sale or other exploitation of that Licensed Product or Licensed Service occurs
in the United States and shall be again be required if Sales of such Licensed Product or Licensed Service are suspended or
discontinued.

 

10.2
Progress reports submitted under Paragraph ‎10.1 shall include such information so that the FUND will be able to
determine whether or not the Licensee has met its diligence obligations set forth in Article ‎9 (Due Diligence)
above:

 

10.2.1 summary
of work completed as of the submission date of the progress report;

 

10.2.2
key scientific discoveries as of the submission date of the progress report;

 

10.2.3
summary of work in progress as of the submission date of the progress report;

 

10.2.4
current schedule of anticipated events and milestones, including those event and milestones specified in
Article ‎9 (Due Diligence);

 

10.2.5
market plans for introduction of Licensed Products and Licensed Services including the anticipated and actual market
introduction dates of each Licensed Product or Licensed Service; and

 

10.2.6
Sublicensees’ activities relating to the above items, if there are any Sublicensees.

 

10.3 Default. If
the Licensee fails to submit a timely progress report to the FUND, then the FUND will be entitled to terminate this Agreement
subject to Article ‎13. If either party terminates this Agreement before any
Licensed Products or Licensed Services are Sold or before this Agreement's expiration, then a final progress report covering
the period prior to termination must be submitted within thirty (30) days after termination or expiration.

 

10.4
First Sale Report. The Licensee will report to the FUND the date of first Sale or other exploitation of a Licensed Product or
Licensed Service in each country in its first progress and royalty reports following such first Sale of a Licensed Product or
Licensed Service.

 

10.5
Quarterly Reports. Beginning with the earlier of (i) the first Sale or other exploitation of a
Licensed Product or Licensed Service or (ii) the first transaction that results in Sublicense Fees accruing to the FUND,
the Licensee will make quarterly Royalty and Sublicensee Royalty reports to the FUND on or before each February 28 (for
the quarter ending December 31), May 31 (for the quarter ending March 31), August 31 (for the quarter
ending June 30) and November 30 (for the quarter ending September 30) of each year. Each Royalty and
Sublicensee Royalty report will cover Licensee's most recently completed calendar quarter and will, at a minimum,
show:

 

    13

     

    

 

10.5.1
the gross invoice prices and Net Sales of Licensed Products or Licensed Services Sold or otherwise exploited (itemizing the
applicable gross proceeds and any deductions therefrom), any Attributed Income (itemizing the applicable gross proceeds and
any deductions therefrom) and any Service Income (itemizing the applicable gross proceeds and any deductions therefrom) due
to the Licensee;

 

10.5.2
the quantity of each type of Licensed Product and/or Licensed Service Sold or otherwise exploited;

 

10.5.3
the country in which each Licensed Product and Licensed Service was made, used or Sold or otherwise
exploited;

 

10.5.4
the Earned Royalties, in United States dollars, payable with respect to Net Sales and Service Income;

 

10.5.5 the
Sublicense Fees, in United States dollars, payable with respect to Attributed Income;

 

10.5.6 the
method used to calculate the Earned Royalty, specifying all deductions taken and the dollar amount of each such
deduction;

 

10.5.7 the
exchange rates used, if any;

 

10.5.8
the amount of the cash and the amount of the cash equivalent of any non-cash consideration including the method used to
calculate the non-cash consideration; and

 

10.5.9
any other information reasonably necessary to confirm Licensee's calculation of its financial obligations
hereunder.

 

10.6 No
Sales Report. If no Sales of Licensed Products and Licensed Services have been made and no Licensed Products and Licensed
Services have been otherwise exploited and no Attributed Income is due to the Licensee during any reporting period, then a
statement to this effect must be provided by the Licensee in the immediately subsequent Earned Royalty and Sublicense Fee
report.

 

11. BOOKS
AND RECORDS

 

11.1
Maintenance of Records. The Licensee will keep accurate books and records showing all Licensed Product under development,
manufactured, used, offered for Sale, imported, Sold and or otherwise exploited; all Licensed Service Sold or otherwise
provided; all Net Sales, all Attributed Income, all Service Income and other amounts payable hereunder; and all sublicenses
granted under the terms of this Agreement. Such books and records will be preserved for the time period in which the Licensee
is required to keep such books and records according to Israeli law after the date of the payment to which they pertain and
will be open to examination by an independent auditor appointed by the FUND at reasonable times and after coordination with
Licensee to determine their accuracy and assess the Licensee's compliance with the terms of this Agreement.

 

    14

     

    

 

11.2
Audit. The FUND shall pay the fees and expenses of such examination and will not make more than one examination each calendar
year. If, however, an error in royalties of more than five percent (5%) of the total royalties due for any year is discovered
in any examination, then the Licensee shall bear the fees and expenses of such examination and shall remit such underpayment
to the FUND within thirty (30) days of the examination results.

 

12. TERM
OF THE AGREEMENT

 

12.1 Life
of Patent Rights. Unless otherwise terminated by operation of law, Paragraph ‎12.2, or by acts of the parties in
accordance with the terms of this Agreement, this Agreement will remain in effect from the Effective Date until the
expiration or abandonment of the last of the Patent Rights licensed hereunder and any extension granted to the FUND, the
Licensee or its designee, whichever is the later. Following the expiration of the Agreement, Licensee shall be granted an
exclusive royalty free license to use in any manner the Know How.

 

12.2 Bankruptcy. This
Agreement will automatically terminate without the obligation to provide 60 days' notice as set forth in
Article ‎13 (Termination By The FUND) if the Licensee is adjudged bankrupt,
applies for judicial or extra-judicial settlement with its creditors, makes an assignment for the benefit of its creditors,
voluntarily files for bankruptcy or has a receiver or trustee (or the like) in bankruptcy appointed by reason of its
insolvency, or in the event an involuntary bankruptcy action is filed against it and not dismissed within ninety (90)
days.

 

    15

     

    

 

 

12.3            Survival.
Any termination or expiration of this Agreement will not affect the rights and obligations set forth in the following Articles:

 

	Article ‎1	Definitions
	 	 
	Paragraph ‎5.6	Late Payments
	 	 
	Article ‎6	Payments on Sublicenses to the extent required under Articles 12.4
	 	 
	Paragraph ‎7.1	Earned Royalties to the extent required under Article 12.4
	 	 
	Article ‎11	Books and Records
	 	 
	Article ‎12	Term of the Agreement
	 	 
	Paragraph 13.2	License Under New Developments
	 	 
	Article ‎14	Disposition of Licensed Products and Licensed Services Upon Termination or Expiration
	 	 
	Article ‎16	Use of Names and Trademarks
	 	 
	Article ‎17	Limited Warranty
	 	 
	Article ‎18	Limitation of Liability
	 	 
	Paragraphs ‎19.4 & ‎19.7	Patent Prosecution and Maintenance
	 	 
	Article ‎22	Indemnification
	 	 
	Article ‎23	Notices
	 	 
	Article ‎27	Governing Laws; Venue; Attorneys Fees
	 	 
	Article ‎30	Confidentiality

 

12.4            Accrued
Obligations. The termination or expiration of this Agreement will not relieve the Licensee of its obligation to pay any
fees, royalties or other payments owed to the FUND at the time of such termination or expiration and will not impair any accrued
right of the FUND, including the right to receive Earned Royalties in accordance with Articles ‎6
(Payments on Sublicenses), ‎7 (Earned Royalties) and ‎14
(Disposition of Licensed Products and Licensed Services Upon Termination or Expiration).

 

13.              TERMINATION

 

13.1            Termination.
If the Licensee fails to perform or violates any material term of this Agreement, then the FUND may give written notice specifying
in reasonable detail the nature of such default ("Notice of Default") to the Licensee. If the Licensee fails to remedy
such default within sixty (60) days after the effective date of such notice, then the FUND will have the right to immediately terminate
this Agreement and its licenses by providing a written notice of termination ("Notice of Termination") to the Licensee.

 

13.2            License
under New Developments . Where this Agreement is terminated by either party for any reason pursuant to this Agreement,
FUND shall have the option to receive from Licensee an exclusive, worldwide, transferable license under any New Developments to
the extent such New Development is necessary for the exploitation or use of the Licensed Technology, by providing written notice
to Licensee to that effect not later than 30 days from the date of termination, and provided that the following conditions are
met:

 

13.2.1          Any
license granted to FUND under the New Development shall be subject to the approval of the entity extending a Grant (including,
without limitation, the Incubators Program of the Office of the Chief Scientist, if applicable), which the parties shall cooperate
to obtain;

 

    	 	16	 

     

    

 

13.2.2         FUND
shall assume all obligations of Licensee in respect of such New Development, including, without limitation, pursuant to Grants
or Government Programs and all royalty obligations and other costs or expenses relating thereto; and

 

13.2.3         Licensors
shall be liable to pay Licensee amounts equivalent to royalties and Sublicense Payments that would have been payable by Licensee
to FUND, as may be generated by FUND, and the provisions of Paragraphs 5, 6, 7, 10, 11, 16 , 17 and 18 shall apply, mutatis
mutandis.

 

13.2.4         If
an agreement for commercialization is not executed between the FUND and a third party within 6 months following the effective date
of the license, then the license terminate and be of no further force and effect.

 

13.2.5         If
termination of this Agreement is due to bankruptcy of Licensee, then any receiver appointed by court shall have the right to cancel
the license at its sole discretion.

 

14.              DISPOSITION
OF LICENSED PRODUCT AND LICENSED SERVICES UPON TERMINATION OR EXPIRATION

 

Upon termination (but not expiration) of
this Agreement, within a period of one hundred and twenty (120) days after the date of termination, the Licensee is entitled to
(i) dispose of all previously made or partially made Licensed Product, and (ii) provide previously contracted-for Licensed
Services, provided that the Sale or use of such Licensed Product and the provision of such Licensed Services are subject to the
terms of this Agreement, including, but not limited to, the rendering of reports and payment of Earned Royalties, Sublicense Fees
and any other payments thereof required under this Agreement. The Licensee will not otherwise make, Sell, offer for Sale or import
Licensed Products or Licensed Services, or practice the Licensed Method after the date of termination.

 

15.             EARNED
ROYALTY. If applicable Patent Rights exist at the time
of any making, Sale, offer for Sale, or import of a Licensed Product or the time of any Sale, offer for Sale, or rendering of a
Licensed Service, then Earned Royalties shall be paid at the times provided herein and royalty reports shall be rendered in connection
therewith, notwithstanding the absence of applicable Patent Rights with respect to such Licensed Product or Licensed Service at
any later time. Otherwise, no Earned Royalties shall be paid on the Sales of such product or service. Any fees or other payments
owed to the FUND at the time of expiration not based on the Sales of a Licensed Product or Licensed Service will be paid to the
FUND at the time such fee or other payment would have been due had this Agreement not expired.

 

    	 	17	 

     

    

 

16.              USE
OF NAMES AND TRADEMARKS

 

Nothing contained
in this Agreement will be construed as conferring any right to either party to use in advertising, publicity or other promotional
activities any name, trade name, trademark or other designation of the other party (including a contraction, abbreviation or simulation
of any of the foregoing). Without the Licensee's consent case-by-case, the FUND may list Licensee's name as a licensee of technology
from the FUND without further identifying the technology. Unless required by law or unless consented to in writing by Executive
Director, Office of Technology Transfer of the FUND, the use by the Licensee of the names ""Tel Aviv Sourasky Medical
Center" and "The Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Medical Center"
in advertising, publicity or other promotional activities is expressly prohibited, notwithstanding, Licensee may disclose the fact
that its technology was originated in Tel Aviv Sourasky Medical Center and licensed to Licensee thereby. Notwithstanding the above,
FUND, TASMC and Researchers shall be given due credit in all advertising, publicity or other promotional activities.

 

17.              LIMITED
WARRANTY

 

17.1            The
FUND warrants to the Licensee that it has the lawful right to grant this license, and that it has the power and authority to execute
and deliver this Agreement, and to perform its obligations hereunder, and is not aware that the execution, delivery and performance
by it of this Agreement and its compliance with the terms and provisions hereof may conflict with or result in a breach of any
of the terms and provisions of or constitute a default under (i) any other right or obligation provided under any other agreement
or obligation that it has with any third party; (ii) the provisions of its charter documents or by-laws; or (iii) any
order, writ, injunction or decree of any court or governmental authority entered against it or by which any of its property is
bound.

 

17.2            The
FUND represents that it is not aware of any third party rights, claims or demands in connection with the rights granted hereunder,
the Patent Rights and any related patents, and has not received any correspondence or claim from any third party alleging any such
infringement.

 

17.3            The
FUND further represents that all employees and consultants who were engaged in development of the Invention and/or Patent Rights
are subject to written agreements or other legally binding provisions to the effect that any rights therein have been fully and
irrevocably assigned to the FUND.

 

17.4            Except
as expressly set forth in this Agreement, this license and the associated Invention, Patent Rights, Licensed Products, Licensed
Services and Licensed Methods are provided by the FUND and TASMC WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE OR ANY OTHER WARRANTY OF ANY KIND, EXPRESS OR IMPLIED. THE FUND AND TASMC MAKE NO EXPRESS OR IMPLIED REPRESENTATION
OR WARRANTY THAT THE INVENTION, PATENT RIGHTS, LICENSED PRODUCTS, LICENSED SERVICES OR LICENSED METHODS WILL NOT INFRINGE ANY PATENT,
COPYRIGHT, TRADEMARK OR OTHER RIGHTS.

 

    	 	18	 

     

    

 

17.5            This
Agreement does not:

 

17.5.1         express
or imply a warranty or representation as to the validity, enforceability, or scope of any Patent Rights; or

 

17.5.2         express
or imply a warranty or representation that anything made, used, Sold, offered for Sale or imported or otherwise exploited under
any license granted in this Agreement is or will be free from infringement of patents, copyrights, or other rights of third parties;
or

 

17.5.3         obligate
the FUND or TASMC to bring or prosecute actions or suits against third parties for patent infringement except as provided in Article ‎21
(Patent Infringement); or

 

17.5.4         confer
by implication, estoppel or otherwise any license or rights under any patents or other rights of the FUND or TASMC other than Patent
Rights, regardless of whether such patents are dominant or subordinate to Patent Rights; or

 

17.5.5         obligate
the FUND or TASMC to furnish any new developments, know-how, technology or information not provided in Patent Rights.

 

18.              LIMITATION
OF LIABILITY

 

NEITHER THE FUND
NOR TASMC WILL BE LIABLE FOR ANY LOST PROFITS, COSTS OF PROCURING SUBSTITUTE GOODS OR SERVICES, LOST BUSINESS, ENHANCED DAMAGES
FOR INTELLECTUAL PROPERTY INFRINGEMENT OR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR OTHER SPECIAL DAMAGES SUFFERED
BY LICENSEE, SUBLICENSEES, OR AFFILIATES ARISING OUT OF OR RELATED TO THIS AGREEMENT FOR ALL CAUSES OF ACTION OF ANY KIND (INCLUDING
TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY AND BREACH OF WARRANTY) EVEN IF THE FUND HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES.

 

19.              PATENT
PROSECUTION AND MAINTENANCE

 

19.1            Prosecution
by The FUND. As long as the Licensee has paid Patent Prosecution Costs as provided for in this Article ‎19
(Patent Prosecution and Maintenance), the Licensee will be responsible and diligently prosecute and maintain the United States
and foreign patents comprising the Patent Rights using counsel of its choice, all in accordance with its sole discretion but in
compliance with the terms of this Agreement and with an effort to preserve the Patent Rights. Licensee will provide the FUND with
copies of all relevant documentation so that the FUND will be informed of the continuing prosecution and compliance with the above.

 

19.2            Licensee’s
Changes. Without derogating from the above, the Licensee shall for Licensee's own account and sole responsibility, be entitled
amend any patent application to include claims or any other changes necessary to protect the products and services contemplated
to be Sold, or the Licensed Method to be practiced, under this Agreement. The Licensee shall prepare all documents and the FUND
agrees to execute the documents and to take additional action as the Licensee reasonably requests in connection therewith.

 

    	 	19	 

     

    

 

19.3            Term
Extension. Without derogating from the above, the Licensee shall be entitled to apply for an extension of the term of any
patent included within the Patent Rights if appropriate under the Drug Price Competition and Patent Term Restoration Act of 1984
and/or European, Japanese and other foreign counterparts of this Law. The Licensee shall prepare all documents for Licensee's own
account and sole responsibility, and additionally in a manner which shall not detract from the defense granted by the "invention"
and patent rights and the FUND agrees to execute the documents and to take additional action as the Licensee reasonably requests
in connection therewith. Licensee shall be liable for all costs relating to such application.

 

19.4            Patent
Prosecution Costs. Following such time that Licensee holds the closing of the Funding, the Licensee will bear the costs
of preparing, filing, prosecuting and maintaining all Israeli and foreign patent applications contemplated by this Agreement ("Patent
Prosecution Costs"). These Patent Prosecution Costs will include, without limitation, patent prosecution costs for the Invention
incurred by the FUND prior to the execution of this Agreement and any patent prosecution costs that may be incurred for patentability
opinions, re-examination, re-issue, interferences, oppositions or inventorship determinations. If Licensee does not agree to pay
any such Patent Prosecution Costs or otherwise chooses to abandon any Patent Rights, Licensee shall give written notice of such
to the FUND within thirty (30) days of such conference, and the FUND shall have the right to terminate this Agreement in connection
with the respective Patent Rights to which payment was not made or which Licensee wishes to abandon.

 

19.5            Pre-Funding
Patent Prosecution Costs. Subject to and at such time that Licensee holds the closing of the Funding, Licensee shall reimburse
the FUND for all past patent prosecution costs in the aggregate amount of approximately NIS211,837 and any further Patent Prosecution
Costs incurred from the Effective Date and until such time (“Pre-Funding Prosecution Costs”). Until the closing of
the Funding time, the FUND will be responsible and diligently prosecute and maintain the United States and foreign patents (including
in India, Japan and China and as shall be further agreed between the parties) comprising the Patent Rights using counsel of its
choice, all in accordance with its sole discretion but in compliance with the terms of this Agreement and with an effort to preserve
the Patent Rights. The FUND will cooperate and coordinate any filing in advance with Licensee and will also coordinate the general
patent strategy pertaining to the Patent Rights. The costs to the FUND hereunder shall not exceed US$20,000 and the Parties shall
coordinate any cost and expense in excess. Reimbursement shall be made upon and subject to the closing of the Funding, and all
such Patent Prosecution Costs shall be deemed part of the Pre-Funding Prosecution Costs.

 

    	 	20	 

     

    

 

19.6            Foreign
Patent Rights. Following the closing of the Funding, the Licensee may request that the FUND obtain patent protection on
the Invention in additional foreign countries, if available and if it so desires. The Licensee will notify the FUND of its decision
to obtain or maintain foreign patents not less than ninety (90) days prior to the deadline for any payment, filing or action to
be taken in connection therewith. This notice concerning foreign filing must be in writing, must identify the countries desired
and must reaffirm the Licensee's obligation to pay the Patent Prosecution Costs thereof. The absence of such a notice from the
Licensee to the FUND will be considered an election not to obtain or maintain foreign Patent Rights.

 

19.7            Post
Termination Patent Costs. With the exception of the Pre-Funding Prosecution Costs, the Licensee will be obligated to pay
any Patent Prosecution Costs incurred during the two (2)-month period after receipt by either party of a Notice of Termination,
even if the invoices for such Patent Prosecution Costs are received by the Licensee after the end of the two (2)-month period following
receipt of a Notice of Termination. Notwithstanding the above, Licensee will be responsible for payment of any Patent Prosecution
Costs incurred for completion of services requested and/or approved by Licensee prior to the effective date of the Notice of Termination,
even if such costs were incurred after the two (2) month period referenced above. The Licensee may terminate its obligation
to pay Patent Prosecution Costs with respect to any given patent application or patent under Patent Rights in any or all designated
countries upon three (3)-months' written notice to the FUND. The FUND may continue prosecution and/or maintenance of such application(s) or
patent(s) at its sole discretion and expense, provided, however, that the Licensee will have no further right or licenses
thereunder. Non-payment of Patent Prosecution Costs may be deemed by the FUND as an election by the Licensee not to maintain such
application(s) or patent(s).

 

19.8            Licensee’s
Election. If Licensee elects not to file (and has no future intention to file), prosecute or maintain patent application
in any specific foreign jurisdiction, the FUND may file, prosecute or maintain patent applications or patents at its own expense
in any country in which the Licensee has not elected to file, prosecute or maintain patent applications or patents in accordance
with this Article ‎19 (Patent Prosecution and Maintenance) and those applications,
resultant patents and patents will not be subject to this Agreement.

 

20.              PATENT
MARKING

 

The Licensee will
mark all Licensed Products made, used or Sold under the terms of this Agreement or their containers in accordance with the applicable
patent marking laws.

 

    	 	21	 

     

    

 

21.              PATENT
INFRINGEMENT

 

21.1            Infringement
Notice. In the event that the FUND (to the extent of the actual knowledge of the licensing professional responsible for
the administration of this Agreement) or the Licensee learns of infringement of potential commercial significance of any patent
licensed under this Agreement, the knowledgeable party will provide the other (i) with written notice of such infringement
and (ii) with any evidence of such infringement available to it (the "Infringement Notice"). During the period in
which, and in the jurisdiction where, the Licensee has exclusive rights under this Agreement, neither The FUND nor the Licensee
will notify a possible infringer of infringement or put such infringer on notice of the existence of any Patent Rights without
first obtaining consent of the other. Both the FUND and the Licensee will use their diligent efforts to cooperate with each other
to terminate such infringement without litigation.

 

21.2            Action
by Licensee. If infringing activity of potential commercial significance by the infringer has not been abated within ninety
(90) days following the date the Infringement Notice takes effect, then the Licensee may institute suit for patent infringement
against the infringer. The FUND may voluntarily join such suit at its own expense, but may not otherwise commence suit against
the infringer for the acts of infringement that are the subject of the Licensee's suit or any judgment rendered in that suit. The
Licensee may not join the FUND as a party in a suit initiated by the Licensee without the FUND's prior written consent unless it
is required since Licensee lacks standing (in which case the Licensee will pay any costs incurred by the FUND arising out of such
suit). If, in a suit initiated by the Licensee, The FUND is involuntarily joined other than by the Licensee, then the Licensee
will pay any costs incurred by the FUND arising out of such suit, including but not limited to, any legal fees of counsel that
the FUND selects and retains to represent it in the suit. Notwithstanding, the FUND shall be represented by the same counsel as
Licensee, unless the FUND has a basis to believe that a conflict of interests exist and requires the FUND to have separate representation.

 

21.3            Action
by the FUND. If, within a hundred and twenty (120) days following the date the Infringement Notice takes effect, infringing
activity of potential commercial significance by the infringer has not been abated and if the Licensee has not brought suit against
the infringer, then the FUND may institute suit for patent infringement against the infringer. If the FUND institutes such suit,
then the Licensee may not join such suit without the FUND's consent and may not thereafter commence suit against the infringer
for the acts of infringement that are the subject of the FUND's suit or any judgment rendered in that suit.

 

21.4            Recovery.
Any recovery or settlement received in connection with any suit will first be shared by the FUND and the Licensee equally to cover
any litigation costs each incurred and next shall be paid to the FUND or the Licensee to cover any litigation costs it incurred
in excess of the litigation costs of the other. In any suit initiated by the Licensee, any recovery in excess of litigation costs
will be shared between Licensee and the FUND to provide the FUND with [***]% of the recovery. In any suit initiated by the Fund,
the FUND shall provide Licensee with [***]% of the recovery. In the event that a suit is initiated by the Licensee prior to the
first anniversary of the Effective Date, then the FUND shall be entitled to [***]% of the recovery.

 

    	 	22	 

     

    

 

21.5            Sublicense.
Any agreement made by the Licensee for purposes of settling litigation or other dispute shall comply with the requirements of Article ‎3
(Sublicenses) of this Agreement.

 

21.6            Cooperation.
Each party will cooperate with the other in litigation proceedings instituted hereunder but at the expense of the party who initiated
the suit (unless such suit is being jointly prosecuted by the parties).

 

21.7            Controlling
Litigation. Any litigation proceedings will be controlled by the party bringing the suit, except that the FUND may be represented
by counsel of its choice in any suit brought by the Licensee if a conflict of interests exists.

 

22.             INDEMNIFICATION

 

22.1            By
Licensee. The Licensee will, and will require its Sublicensees to, indemnify, hold harmless and defend the FUND and TASMC,
the sponsors of the research that led to the Invention and the inventors of any invention claimed in patents or patent applications
under Patent Rights (including the Licensed Products, Licensed Services and Licensed Methods contemplated thereunder) and their
employers, and the officers, employees and agents of any of the foregoing, against any and all claims, suits, losses, damage, costs,
fees and expenses ("Claim") resulting from, or arising out of, the exercise of this license or any sublicense, provided
however that the basis of such Claim is not: (a) the willful misconduct or omission of any of the indemnified parties; and/or
(b) a claim that the Patent Rights infringe third party rights. This indemnification will include, but not be limited to,
any product liability.

 

22.2            Later
Insurance. Notwithstanding the above, no later than the earlier of: i) sixty (60) days before the anticipated date of market
introduction of any Licensed Product or Licensed Service; or ii) sixty (60) days before the first use of any Licensed Product or
Licensed Service in a human under this Agreement, the Licensee, at its sole cost and expense, shall insure its activities in connection
with any work performed under this Agreement and obtain, keep in force and maintain the insurance which is reasonable and customary
for such activities.

 

General.            If
the insurance obtained is written on a claims-made form, it shall continue for three (3) years following termination or expiration
of this Agreement. The insurance shall have a date of placement coinciding with a date no later than the earlier of: sixty (60)
days before the anticipated date of market introduction of any Licensed Product or Licensed Service or sixty (60) days before the
first use of any Licensed Product or Licensed Service in a human.

 

    	 	23	 

     

    

 

The insurance shall
be further in compliance with the following:

 

		-	Provide for thirty (30) days' (ten (10) days for non-payment of premium) advance written notice
to The FUND of any cancellation of insurance coverage; the Licensee will promptly notify The FUND of any material modification
of the insurance coverage;

 

		-	Indicate that the FUND and TASMC have been endorsed as an additional insured;

 

		-	the insurance policy shall include a cross-liability provision and no right of subrogation, and

 

		-	Include a provision that the coverage will be primary and will not participate with, nor will be
excess over, any valid and collectable insurance or program of self-insurance maintained by the FUND and/or TASMC.

 

22.3            Notice
of Indemnification. The insurance coverage will not in any way limit the liability of the Licensee under its indemnification
obligation, however shall serve as first recourse.

 

22.4            The
FUND will promptly notify the Licensee in writing of any claim or suit brought against the FUND for which the FUND intends to invoke
the provisions of this Article 22 (Indemnification) and if no such timely notice is provided and Licensee's ability to defend
such claim or suit is adversely affected, then Licensee shall be released of its undertaking to indemnify the FUND hereunder. The
Licensee will keep the FUND informed of its defense of any claims pursuant to this Article ‎22
(Indemnification). The Licensee shall, upon its acknowledgment in writing of its obligation to indemnify the FUND, be entitled
to and shall assume the defense or represent the interests of the FUND in respect of such Claim, that shall include the right to
select and direct legal counsel and other consultants to appear in proceedings on behalf of the FUND and to propose, accept or
reject offers of settlement, all at its sole cost; provided, however, that no such settlement shall be made without the written
consent of the FUND, such consent not to be unreasonably withheld. Nothing herein shall prevent the FUND from retaining its own
counsel and participating in its own defense at its own cost and expense. If the FUND, in its sole discretion, believes that there
will be a conflict of interest or it will not otherwise be adequately represented by counsel chosen by the Licensee to defend The
FUND in accordance with this Paragraph ‎22.4, then the FUND may retain counsel of its
choice to represent it and the Licensee will pay all reasonable expenses for such representation.

 

    	 	24	 

     

    

 

23.              NOTICES

 

23.1            Any
notice or payment required to be given to either party under this Agreement will be in writing and will be deemed to have been
properly given and to be effective as of the date specified below if delivered to the respective address given below or to another
address as designated by written notice given to the other party:

 

23.1.1         on
the next business day following delivery if delivered in person, by fax or by e-mail;

 

23.1.2         on
the 7th business day following mailing if mailed by first-class certified mail, postage paid; or

 

23.1.3         on
the 7th business day following mailing if mailed by any global express carrier service that requires the recipient to
sign the documents demonstrating the delivery of such notice or payment.

 

	In the case of Licensee:	ChemomAb Ltd.
	 	Address: 5 Azrieli Center
	 	Tel Aviv
	 	c/o Horn &Co., Law Offices
	 	Attention: Yuval Horn, Adv.
	 	Fax: [***]
	 	 
	In the case of the FUND:	The Medical Research Infrastructure and Health Services Fund near the Tel Aviv Souraski Medical Center
	 	Address: 6 Weitzman Street Tel Aviv, Israel
	 	Attention: Dr. Michal Roll
	 	Fax: [***]

 

24.              ASSIGNABILITY

 

This
Agreement is personal to the Licensee. The Licensee may not assign or transfer this Agreement without the FUND's prior written
consent except, however, that the Licensee may assign this Agreement to any entity which acquires the Licensee by merger or purchase
of substantially all of the assets of the Licensee, provided that such assignee or transferee promptly agrees to be bound by the
terms and conditions of this Agreement and Licensee and such assignee or transferee signs the FUND's standard substitution of party
letter (the form of which is attached hereto as Appendix A). Any attempted assignment by the Licensee in violation of this Article ‎24
(Assignment) will be null and void. This Agreement is binding upon and will inure to the benefit of the FUND, its successors and
assigns.

 

    	 	25	 

     

    

 

25.              WAIVER

 

No waiver by either
party of any breach or default of any of the agreements contained herein will be deemed a waiver as to any subsequent and/or similar
breach or default. No waiver will be valid or binding upon the parties unless made in writing and signed by a duly authorized officer
of each party.

 

26.              FORCE
MAJEURE

 

26.1            General.
Except for the Licensee's obligation to make any payments to the FUND hereunder, the parties shall not be responsible for any failure
to perform due to the occurrence of any events beyond their reasonable control which render their performance impossible or onerous,
including, but not limited to: accidents (environmental, toxic spill, etc.); acts of God; biological or nuclear incidents;
casualties; earthquakes; fires; floods; governmental acts; orders or restrictions; inability to obtain suitable and sufficient
labor, transportation, fuel and materials; local, national or state emergency; power failure and power outages; acts of terrorism;
strike; and war.

 

26.2            Limit.
Either party to this Agreement, however, will have the right to terminate this Agreement upon thirty (30) days’ prior written
notice if either party is unable to fulfill its obligations under this Agreement due to any of the causes specified in Paragraph
‎26.1 for a period of one (1) year.

 

27.              GOVERNING
LAWS; VENUE; ATTORNEYS’ FEES

 

27.1            Israeli
Laws. This Agreement will be interpreted and construed in accordance with the laws of the State of Israel, excluding any choice
of law rules that would direct the application of the laws of another jurisdiction and without regard to which party drafted
particular provisions of this Agreement, but the scope and validity of any patent or patent application will be governed by the
applicable laws of the country of such patent or patent application.

 

27.2            Venue.
Any legal action brought by the parties hereto relating to this Agreement will be conducted in Tel Aviv, Israel.

 

27.3            Attorney’s
Fees. The prevailing party in any suit related to this Agreement will be entitled to recover its reasonable attorneys'
fees in addition to its costs and necessary disbursements.

 

    	 	26	 

     

    

 

28.              GOVERNMENT
APPROVAL OR REGISTRATION

 

If this Agreement
or any associated transaction is required by the law of any nation to be either approved or registered with any governmental agency,
the Licensee will assume all legal obligations to do so. The Licensee will notify the FUND if it becomes aware that this Agreement
is subject to a Israeli or foreign government reporting or approval requirement. The Licensee will make all necessary filings and
pay all costs including fees, penalties and all other out-of-pocket costs associated with such reporting or approval process.

 

29.              COMPLIANCE
WITH LAWS

 

The Licensee shall
comply with all applicable international, national, state, regional and local laws and regulations in performing its obligations
hereunder and in its use, manufacture, Sale or import of the Licensed Products, Licensed Services or practice of the Licensed Method.
The Licensee will observe all applicable Israeli and foreign laws with respect to the transfer of Licensed Products and related
technical data and the provision of Licensed Services to foreign countries.

 

30.              CONFIDENTIALITY

 

30.1            Proprietary
Information. The Licensee and the FUND will treat and maintain the other party’s proprietary business, patent prosecution,
software, engineering drawings, process and technical information and other proprietary information, including the negotiated terms
of this Agreement and any progress reports and royalty reports and any sublicense agreement issued pursuant to this Agreement ("Proprietary
Information") in confidence using at least the same degree of care as the receiving party uses to protect its own proprietary
information of a like nature from the date of disclosure until five (5) years after the termination or expiration of this
Agreement.

 

30.2            Confidentiality.
The Licensee and the FUND may use and disclose, to the extent necessary under this Agreement, the Proprietary Information of the
other party to their employees, agents, consultants, contractors and, in the case of the Licensee, its Sublicensees, and in the
case of the FUND, to TASMC, provided that such parties are bound by a like duty of confidentiality as that found in this Article ‎30
(Confidentiality). Notwithstanding anything to the contrary contained in this Agreement, the FUND and TASMC may release this Agreement
or any sublicense, including any terms thereof, and information regarding royalty payments or other income received in connection
with this Agreement to the inventors, senior administrative officials and in the case of the FUND, to individual Regents upon their
request. If such release is made, the FUND and TASMC will request that such terms be kept in confidence in accordance with the
provisions of this Article ‎30 (Confidentiality). In addition, notwithstanding anything
to the contrary in this Agreement, if a third party inquires whether a license to Patent Rights is available, then the FUND may
disclose the existence of this Agreement and the extent of the grant in Articles ‎2 (Grant)
and ‎3 (Sublicenses) and related definitions to such third party, but will not disclose
the name of the Licensee unless Licensee has already made such disclosure publicly. In addition, Licensee may disclose, on a confidential
basis, the terms of this Agreement to potential investors, acquirers or sublicensees in the process of due diligence reviews of
the Licensee’s contracted obligations, assets and undertakings.

 

    	 	27	 

     

    

 

30.3            Exceptions.
Nothing contained herein will restrict or impair, in any way, the right of the Licensee, the FUND or TASMC to use or disclose any
Proprietary Information:

 

30.3.1         that
recipient can demonstrate by written records was previously known to it prior to its disclosure by the disclosing party;

 

30.3.2         that
recipient can demonstrate by written records is now, or becomes in the future, public knowledge other than through acts or omissions
of recipient;

 

30.3.3         that
recipient can demonstrate by written records was obtained lawfully and without restrictions on the recipient from sources independent
of the disclosing party; and

 

30.3.4         that
the recipient is required to disclose pursuant to an applicable law.

 

The Licensee or the FUND also may disclose
Proprietary Information that is required to be disclosed (i) to a governmental entity or agency in connection with seeking
any governmental or regulatory approval, governmental audit, or other governmental contractual requirement or (ii) by law,
provided that the recipient uses reasonable efforts to give the party owning the Proprietary Information sufficient notice of such
required disclosure to allow the party owning the Proprietary Information reasonable opportunity to object to, and to take legal
action to prevent, such disclosure.

 

30.4            Return
or Destroy. Upon termination of this Agreement, the Licensee and the FUND will destroy or return any of the disclosing
party’s Proprietary Information in its possession within fifteen (15) days following the termination of this Agreement. The
Licensee and the FUND will provide each other, within thirty (30) days following termination, with written notice that such Proprietary
Information has been returned or destroyed. Each party and TASMC may, however, retain one copy of such Proprietary Information
for archival purposes in non-working files.

 

31.              MISCELLANEOUS

 

31.1            Headings.
The headings of the several sections are inserted for convenience of reference only and are not intended to be a part of or to
affect the meaning or interpretation of this Agreement.

 

31.2            Signing.
This Agreement is not binding on the parties until it has been signed below on behalf of each party. It is then effective as of
the Effective Date.

 

31.3            Amendment.
No amendment or modification of this Agreement is valid or binding on the parties unless made in writing and signed on behalf of
each party.

 

    	 	28	 

     

    

 

31.4            Entirety.
This Agreement embodies the entire understanding of the parties and supersedes all previous communications, representations or
understandings, either oral or written, between the parties relating to the subject matter hereof.

 

31.5            Attachments.
This Agreement includes the attached Appendix A.

 

31.6            Invalidity.
In case any of the provisions contained in this Agreement is held to be invalid, illegal or unenforceable in any respect, such
invalidity, illegality or unenforceability will not affect any other provisions of this Agreement and this Agreement will be construed
as if such invalid, illegal or unenforceable provisions had never been contained in it.

 

31.7            No
Third Party Beneficiary. No provisions of this Agreement are intended or shall be construed to confer upon or give to any
person or entity other than the FUND and the Licensee any rights, remedies or other benefits under, or by reason of, this Agreement.

 

31.8            Independent
Contractor. In performing their respective duties under this Agreement, each of the parties will be operating as an independent
contractor. Nothing contained herein will in any way constitute any association, partnership, or joint venture between the parties
hereto, or be construed to evidence the intention of the parties to establish any such relationship. Neither party will have the
power to bind the other party or incur obligations on the other party's behalf without the other party's prior written consent.

 

IN WITNESS WHEREOF,
both the FUND and the Licensee have executed this Agreement, in duplicate originals, by their respective and duly authorized officers
on the day and year written.

 

Medical
Research, Infrastructure, Health Services Fund of the Tel-Aviv Souraski Medical Center

 

	By:	/s/ YARIV HELLMAN	 
	 	Name:	YARIV HELLMAN	 
	 	Title:	CFO	 
	 	 	 	 
	By:	/s/ DR MICHAL ROLL	 
	 	Name:	 DR MICHAL ROLL	 
	 	Title:	R&D Director	 
	 	 	 	 
	Chemomab Ltd.	 
	 	 	 	 
	By:	/s/ Adi Mor	 
	 	Name:	Adi Mor	 
	 	Title:	CSO	 

 

    	 	29	 

     

    

 

EXCLUSIVE LICENSE AGREEMENT

 

 

between

 

 

THE MEDICAL RESEARCH, INFRASTRUCTURE,
HEALTH SERVICES FUND OF THE TEL-AVIV SOURASKI TASMC

 

 

and

 

 

CHEMOMAB LTD.

 

    	 	30	 

     

    

 

TABLE OF CONTENTS

 

	Article No.	Title	Page
	 	 	 
	1.	DEFINITIONS	2
	 	 	 
	2.	GRANT	5
	 	 	 
	3.	SUBLICENSES	6
	 	 	 
	4.	MANDATORY SUBLICENSING	7
	 	 	 
	5.	PAYMENT TERMS	8
	 	 	 
	6.	PAYMENTS ON SUBLICENSES	9
	 	 	 
	7.	EARNED ROYALTIES	10
	 	 	 
	8.	MILESTONE PAYMENTS	10
	 	 	 
	9.	DUE DILIGENCE	11
	 	 	 
	10.	PROGRESS AND ROYALTY REPORTS	13
	 	 	 
	11.	BOOKS AND RECORDS	14
	 	 	 
	12.	TERM OF THE AGREEMENT	15
	 	 	 
	13.	TERMINATION	16
	 	 	 
	14.	DISPOSITION OF LICENSED PRODUCT AND LICENSED SERVICES UPON TERMINATION OR EXPIRATION	17
	 	 	 
	15.	EARNED ROYALTIES	18
	 	 	 
	16.	USE OF NAMES AND TRADEMARKS	18
	 	 	 
	17.	LIMITED WARRANTY	18
	 	 	 
	18.	LIMITATION OF LIABILITY	19
	 	 	 
	19.	PATENT PROSECUTION AND MAINTENANCE	19
	 	 	 
	20.	PATENT MARKING	21
	 	 	 
	21.	PATENT INFRINGEMENT	22
	 	 	 
	22.	INDEMNIFICATION	23
	 	 	 
	23.	NOTICES	25
	 	 	 
	24.	ASSIGNABILITY	25
	 	 	
	25.	WAIVER	26
	 	 	 
	26.	FORCE MAJEURE	26
	 	 	 
	27.	GOVERNING LAWS; VENUE; ATTORNEYS’ FEES	26
	 	 	 
	28.	GOVERNMENT APPROVAL OR REGISTRATION	27
	 	 	 
	29.	COMPLIANCE WITH LAWS	27
	 	 	 
	30.	CONFIDENTIALITY	27
	 	 	 
	31.	MISCELLANEOUS	28

 

APPENDIX
A

 

APPENDIX
B

 

    	 	31Exhibit 10.9

 

 

 

Certain information in this document, marked by brackets, has been excluded pursuant to Item 601(b)(10)(iv)
of Regulation S-K under the Securities Act of 1933, as amended, because it is both (i) not material and (ii) would likely cause
competitive harm to the registrant if publicly disclosed.

 

CHEF1 NON-EXCLUSIVE LICENSE AGREEMENT

 

This CHEF1 non-exclusive license agreement (“Agreement”),
effective as of 7th  June 2015 (“Effective Date”), is made by and between CMC
ICOS Biologics, Inc., a Washington corporation having its principal offices at 22021 20th Avenue S.E., Bothell,
WA 98021 (“CMC ICOS”), and ChemoMab Ltd. an Israeli corporation having its principal offices at 6 Hanehoshet St. Tel
Aviv, Israel (“Licensee”).

 

WHEREAS, CMC ICOS has
proprietary rights in and to [***] (“CHEF1”) and Materials (defined below) and know-how in the techniques and use of
the same (collectively “CHEF1 Technology”), as described in part in the Patent Rights (defined below);

 

WHEREAS, Licensee desires
a limited research license to use CHEF1 Technology to develop and produce research quantities of protein products that are owned
or controlled by Licensee as described below; and

 

WHEREAS, the parties
desire the security of a relationship in which Licensee has an option to obtain a commercial license to use CHEF1 Technology at
a predictable rate and CMC ICOS has a continual graduated revenue stream during the development of Licensee’s protein products
through to Regulatory Approval (defined below) and sale of Licensee Products (defined below) as human diagnostics or therapeutics.

 

NOW THEREFORE, the
parties agree as follows:

 

1.             Definitions

 

For purposes of this
Agreement, the following terms have the meanings defined below:

 

1.1       “Affiliate”
of a specified entity means an entity that directly or indirectly controls, is controlled by, or is under common control with,
the specified entity. For purposes of this definition, the direct or indirect ownership of more than 50% of the outstanding voting
shares of an entity or the right to appoint the majority of the representatives to the board or direct the management of the entity
will be deemed to constitute control.

 

1.2       “BLA”
means a Biologics License Application (as used in the United States Food, Drug & Cosmetics Act and associated regulations)
or any regulatory application equivalent thereto (as used in any corresponding foreign law or regulation) for Regulatory Approval.

 

1.3       “Clinical
Trial” means any clinical trial involving administration of a Licensee Product to a human in any country.

 

    - 1 -

     

    

 

 

1.4       “Confidential
Information” means: (a) all information and materials in tangible form, which includes electronic transmissions,
disclosed and marked as proprietary or confidential by the party disclosing the same (“Disclosing Party”)
at such time as it is delivered to the other party (“Receiving Party”); and (b) all information disclosed
orally hereunder which is identified as confidential or proprietary when disclosed to Receiving Party and such is confirmed
in writing within 30 days by the Disclosing Party. Confidential Information shall not include information that: (i) through
no act or omission of the Receiving Party, is or becomes available to the public; (ii) was or becomes lawfully available on a
non-confidential basis to the Receiving Party; or (iii) is shown by written records of the Receiving Party to have been
independently developed by or for the Receiving Party without access to or knowledge of the Confidential Information of the
Disclosing Party.

 

1.5       
 “Licensee Product(s)” means any protein or fragment thereof owned or for which Licensee has the necessary power,
including due to ownership, to require that the research, development, manufacturing, marketing, sale, offer for sale, importation
and other transfer of such protein or fragment thereof complies with all the provisions of this Agreement, and that: (a) is or
was covered by, infringes or would infringe but for 35 U.S.C. §271(e)(1) or similar legal protection in the U.S. or other
countries the Patent Rights; or (b) is produced in a manner that is or was covered by, infringes or would infringe but for 35 U.S.C.
 §271(e)(1) or similar legal protection in the U.S. or other countries the Patent Rights or (c) uses any of the know-how comprised
within the CHEF1 Technology.

 

1.6       “Materials”
means [***], as described in Exhibit A.

 

1.7       “Net
Sales” means the gross sales amount invoiced for all bona fide and arm’s length sales or disposals of Licensee
Products by Licensee or its Sublicensees, to any third party less only: (a) any customary quantity, trade or cash discounts actually
given, allowed or taken; (b) amounts actually repaid or credited by Licensee or its Sublicensees (as applicable) against such gross
sales amount by reason of rejection return or recall; (c) reasonable quantities of products used for clinical trials purposes and/or
compassion clinical experiments (whether imposed by law or initiated by the Licensee to the extent no payment is made in connection
therewith); (d) freight and insurance expenses paid by or on behalf of Licensee or its Sublicensees (as applicable) in respect
of such sales; and (e) any sales, use or excise taxes (including value added taxes), customs, duties or other governmental taxes
levied on the sale of a Licensee Product (but specifically excluding income tax and the like), actually included in the invoiced
amount and paid by or on behalf of Licensee or its Sublicensees.

 

In the event Licensee
Products are transferred for less than fair market value, or other than to third parties, Licensee Products shall be deemed to
have been sold at the average invoiced amount obtained in then-current arms-length transactions. Net Sales accrue with the first
commercial sale of the Licensee Products (the "First Commercial Sale").

 

1.8       “Option
Period” for each Licensee Product means the period of time from: (a) the Effective Date of this Agreement until 30 days
after the date of Phase III Clinical Trials were commenced; or (b) any day after the last date in (a) until 30 days after the first
Regulatory Approval for such Licensee Product.

 

1.9       “Patent
Rights” means any of the Valid Claims in United States Patent number [***] and all U.S. and foreign applications and
patents based thereon or claiming priority thereto or common priority therewith, including any continuations, divisionals, reexaminations,
reissues, substitutes, renewals or extensions of any of the foregoing.

 

    - 2 -

     

    

 

 

 

1.10       “Regulatory
Approval” means any official governmental approval (including, where applicable, pricing approval) required to market
a product for a disease or condition in accordance with the applicable laws and regulations of the given country, for example and
without limitation, approval of a BLA or a New Drug Application by the U.S. Food and Drug Administration.

 

1.11       “Royalty
Period” means any calendar quarter beginning on January 1, April 1, July 1, or October 1 of any year during the Term.

 

1.12       “Sublicensee(s)”
means any third party, including Affiliates, that directly or indirectly receives through Licensee any rights under those rights
granted to Licensee hereunder.

 

1.13       “Term”
means: (a) for the Research License, the period of time from the Effective Date, and unless earlier terminated as provided in Section
9 below, shall continue in full force and effect until the end of the Option Period and (b) for a particular Commercial License
granted in accordance with this Agreement on a Licensee Product unless earlier terminated as provided in Section 9 below, the period
of time from the date CMC ICOS receives notice and payment for such Licensee Product, as provided for in Section 2.3, until the
later of the (i) date of the tenth anniversary of the Regulatory Approval of the applicable Licensee Product; or (ii) the last
to expire of the Patent Rights on a Licensee Product-by-Licensee Product and a country-to-country basis.

 

1.14       “Valid
Claim” means, on a country-by-country basis, any claim in:

 

(a) any pending patent
application within the Patent Rights that has: (i) not been pending in such country for more than 10 years from request for examination;
(ii) been asserted and continues to be prosecuted in good faith; or (iii) has not been abandoned or finally rejected without the
possibility of appeal or refilling; or

 

(b) any issued and
unexpired patent within the Patent Rights that has not been: (i) abandoned; (ii) lost through an interference proceeding; (iii)
held permanently revoked, unenforceable, unpatentable or invalid by a non-appealable or unappealed within the time allowed for
appeal order of a court or governmental body of competent jurisdiction; or (iv) rendered unenforceable through disclaimer.

 

2.             Research
License, Option and Commercial License

 

2.1       Research
License. Subject to the terms of this Agreement and Licensee’s compliance therewith, CMC ICOS hereby grants to Licensee
a non-exclusive, worldwide, non-transferable, non-sublicenseable license under the Patent Rights to develop, manufacture and have
manufactured Licensee Products solely for the research, development and clinical activities of Licensee (“Research License”).
Licensee shall enter into a written agreement consistent with the terms of this Agreement with any party manufacturing Licensee
Product (“Subcontractor”), and Licensee shall remain liable for each Subcontractor’s actions and omissions.
CMC ICOS shall provide to Licensee the requested Materials in reasonably agreeable amounts within 30 days of the Effective Date
for Licensee’s use in accordance with the rights licensed to it hereunder. CMC ICOS has no other obligation to Licensee regarding
the CHEF1 Technology other than as set forth herein.

 

    - 3 -

     

    

 

 

 

2.2       Commercial
License. Subject to the terms of this Agreement and Licensee’s compliance therewith, CMC ICOS hereby grants to
Licensee the option, during the Option Period only to acquire, subject to the terms of this Agreement and Licensee’s
compliance therewith, a non-exclusive, worldwide, non-transferable (other than in connection with an M&A transaction of
Licensee), sublicenseable license, under the Patent Rights to make, have made, manufacture, have manufactured, use, sell,
offer for sale and import a Licensee Product (“Commercial License”). Unless Licensee shall have obtained
and continuously maintains a Commercial License on a particular Licensee Product as prescribed in Section 2 and 3, Licensee
shall not: (a) make or have made such Licensee Product other than as provided for in Section 2.1 (i.e., in accordance with
the Research License); or (b) sell, offer for sale, or import such Licensee Product. A separate Commercial License shall be
required for each Licensee Product. For the purpose hereof, M&A transaction shall mean a merger with, or sale of all or
substantially all the assets of Licensee to a third party, provided such third party shall agree in writing to be bound by
the terms hereof as an original party hereto.

 

2.3       Exercise
of the Option. To exercise its option for any given Licensee Product, Licensee must, within the Option Period for such Licensee
Product: (a) provide written notice to CMC ICOS identifying the affected Licensee Product; and (b) pay to CMC ICOS a non-refundable,
non-creditable amount of either: (i) $[***], if paid during the Option Period as defined in Section 1.8(a); or (ii) $[***], if
paid during the Option Period as defined in Section 1.8(b). Upon the acquisition of the Commercial License, CMC ICOS shall convey
the CHEF1 Technology (including applicable know-how) to the extent applicable to Licensee Products to the Licensee and provide
reasonable assistance to the Licensee in implementing the same.

 

2.4        Commercial
License. CMC ICOS shall have no obligation to grant any Commercial License for any given Licensee Product or otherwise make
available any rights to Licensee unless Licensee has made all payments and provided the notices at the time such payments and notices
are due to CMC ICOS pursuant to: (a) Sections 2.3 and 3.1 - 3.2 for such Licensee Product for which Licensee is exercising its
option under Section 2.3; and (b) Sections 2.3 and 3.1-3.3 for all other Licensee Products for which Licensee has been granted
a Commercial License, if any. The value of the consideration required by Licensee, including for the Commercial License, was established
for the convenience of the parties and is acceptable to CMC ICOS as appropriate consideration only if payments are received in
the amount and at the development intervals stated herein reflecting value in all aspects of the CHEF1 Technology.

 

2.5       No
Modifications. Licensee agrees that it shall not modify any CHEF1 Technology except to [***]. If, notwithstanding the foregoing
covenant, Licensee makes any other modification to any CHEF1 Technology, then, in addition to other remedies that may be available
to CMC ICOS, Licensee shall notify CMC ICOS of such modification, and hereby assigns to CMC ICOS all right, title and interest,
throughout the world, in and to any and all intellectual property arising out of such modification, whether patentable or not,
and all know-how and tangible materials related thereto. In such case, Patent Rights shall be deemed to include all U.S. and foreign
applications and patents claiming such modification, including any continuations, continuations-in-part, divisionals, all patents
issuing therefrom, reexaminations, reissues, substitutes, renewals or extensions of and supplementary certificates allowed on any
of the foregoing, without otherwise modifying the terms of this Agreement.

 

2.6       No
Third Party Services or Products. Notwithstanding anything to the contrary, no right, title, or interest is or will be
conveyed to Licensee to: (a) develop, make, have made, use, sell, offer for sale, import or otherwise make available any
CHEF1 Technology on a stand-alone basis, including as a separate product or service; or (b) develop, make, have made, use,
sell, offer for sale or import or otherwise make available any product other than a Licensee Product, including using any
CHEF1 Technology to [***]. Any attempt to convey rights in contravention of this Section 2.6 shall be null and void.

 

    - 4 -

     

    

 

 

 

2.7       No
Implied Licenses or Sale. Nothing contained in this Agreement shall be construed as conferring, by implication, estoppel, or
otherwise, upon Licensee, any party in privity with Licensee, or any customer of the foregoing, any right, title or interest under
any patent rights, including the Patent Rights, or other intellectual or tangible property rights owned or controlled by CMC ICOS
at any time, except for those rights expressly granted in Sections 2.1 and 2.2 in accordance with their terms. Nothing shall be
deemed to constitute a sale of the CHEF1 Technology, including the Materials, which Licensee agrees not to purport to sell or to
transfer to any party (other than as part of the Licensee Products, and then in accordance with the terms of the Research License
or the Commercial License as applicable). All rights, title and interest not expressly conveyed herein are reserved by CMC ICOS.

 

2.8       Patent
Rights. Licensee agrees that CMC ICOS is under no obligation to prosecute, maintain, enforce or defend the Patent Rights. Nevertheless,
each party shall notify the other in the event it receives notice during the Term of any claim or proceeding brought or threatened
by a third party alleging the invalidity in whole or in part of the Patent Rights. CMC ICOS shall have the sole right but not the
obligation to bring or defend any action to enforce or protect any of the Patent Rights. Licensee agrees that it shall, at CMC
ICOS’s request and expense, join and cooperate as it deems reasonable with any such reasonably action and, to the extent
possible and as it deems reasonable, have its employees testify when requested and make available relevant records, papers, information,
samples, specimens, and the like, all as it deems reasonable and provided that such information or assistance is not detrimental
to Licensee..

 

3.            Consideration

 

3.1       [***]
Fees. Licensee shall pay to CMC ICOS the following [***] fees, [***], which payments shall be non-refundable and non-creditable
toward any future payment due CMC ICOS:

 

(a)       $[***]
within 30 days after [***]; and

 

(b)       $[***]
within 30 days after [***]; and

 

(c)       $[***]
within 30 days of [***].

 

3.2       Milestones.
Licensee shall notify CMC ICOS upon the occurrence of the following events for each Licensee Product and pay to CMC ICOS the following
non-refundable and non-creditable milestones for each Licensee Product:

 

(a)       $[***]
within 30 days after [***];

 

(b)       $[***]
within 30 days after [***]; and

 

(c)       $[***]
within 30 days after [***].

 

    - 5 -

     

    

 

 

 

3.3       Commercial
License Royalty. Licensee shall pay to CMC ICOS a quarterly royalty payment in the amount of [***]% of Net Sales of each
Licensee Product in a Royalty Period, which royalty shall be due 45 days after the end of each such Royalty Period. No
multiple royalties shall be due on any particular Licensee Product if such Licensee Product is covered by more than one Valid
Claim of the Patent Rights. CMC ICOS will waive royalty payments for so long as Licensee (and its Sub-licensees) engages CMC
ICOS (or its affiliates) to exclusively manufacture the Licensee Product. The Parties acknowledge that the above royalty is
reflective of the value attributable to the know-how in the CHEF1 Technology

 

4.            Conditions
of Sublicensing

 

Licensee shall have
the right to sublicense any Commercial License granted in accordance with the terms of this Agreement so long as Licensee: (a)
provides to CMC ICOS the name of each Sublicensee, the date such sublicense was granted and the Licensee Product to which the sublicense
pertains; (b) ensures, and provides written verification to CMC ICOS that each and every sublicense agreement is consistent with
all the terms and conditions of this Agreement and states that the sublicense shall terminate if the corresponding Commercial License
terminates (or it shall be null and void); and (c) remains expressly liable for all actions and/or omissions of any of its Sublicensees.

 

5.            Records,
Payments and Notices

 

5.1       Licensee
Records. Licensee shall report the date of First Commercial Sale for each Licensee Product on a country-by-country basis. Licensee
and Sublicensees shall keep and maintain continuous, complete and accurate records and books relating to any payment required to
be made under Section 3 for 3 years following the year in which such payment accrued. Each royalty payment made by Licensee shall
be accompanied by an accounting specifically listing each Licensee Product, and the Net Sales calculation for such Licensee Product
attributable to Licensee and each Sublicensee, including a reporting of any applicable deductions, conversions, allowances and
charges. If no payment is due for Licensee Product, Licensee shall so report.

 

5.2       Manner
and Form of Payments. All payments due hereunder shall be paid without additional invoice, by wire transfer in United States
dollars in immediately available funds, to an account designated by CMC ICOS. For purposes of computing royalty payments for Net
Sales outside the United States, such royalties shall be converted into United States dollars by applying the rate of exchange
quoted in The Wall Street Journal on the last business day of the applicable Royalty Period, and all banking transfer fees in connection
with payment shall be borne by Licensee. Late payments for any payments due under the Research License and the Commercial License,
if any, shall be bear an annual interest, compounded monthly, equal to [***] percent ([***]%) [***] as determined for each month on the last business day of that month, assessed from the day the payment was initially
due until the date of actual payment.

 

    - 6 -

     

    

 

 

 

5.3       Audits.
Upon reasonable notice from CMC ICOS, but no more than once per calendar year and during normal business hours, Licensee
shall permit an independent certified public accountant in good standing and appointed by CMC ICOS, to examine its records
and any documentation regarding audits Licensee may conduct for any of its Subcontractors and/or Sublicensees. If there are
not adequate books and records to determine Subcontractors’ and/or Sublicensees’ compliance, Licensee shall
perform audit(s) and make its conclusion available to CMC ICOS or otherwise allow an independent certified accountant
designated on behalf of CMC ICOS to perform such audit(s) on its behalf. These records shall be treated as Confidential
Information. Any such audit shall be at the expense of CMC ICOS, unless such audit reveals an underpayment of more than 7% in
any reporting period, in which case Licensee shall pay all actual and documented expenses related thereto. Any underpayment
shall be immediately paid to CMC ICOS with interest as set forth in Section 5.2. Any overpayment shall be settled upon
subsequent payment.

 

5.4       Notices.
Any notice or other communication pursuant to this Agreement will be sufficiently made or given on the date of mailing if sent
to such party by certified, first-class mail, postage prepaid and made out to the party at its address below or as may be otherwise
designated by written notice:

 

	 	CMC ICOS:	Business Development

CMC ICOS Biologics, Inc.

22021 20th Avenue
S.E.

Bothell, WA 98021

		Licensee:	ChemoMab Ltd.

6 Hanehoshet

St. Tel Aviv,

Israel

 

6.             Representations,
Warranties and Disclaimers 

 

6.1       CMC
ICOS Representations, Warranties and Disclaimers. CMC ICOS represents and warrants that as of the Effective Date it: (a) is
the sole owner of record of the Patent Rights; (b) has all necessary right and authority to enter into this Agreement; and (c)
has not received any notice or complaint alleging that the making, using, selling, or offering for sale in the U.S., or the importation
into the U.S., of CHEF1 Technology infringes any U.S. patent rights of any third party; and (d) the Research License and Commercial
License to the Patent Rights are lawfully granted hereunder. CMC ICOS warrants that so far as its management are aware (it being
acknowledged that CMC ICOS is not required to undertake any freedom to operate search or seek professional advice) the use of the
CHEF1 Technology does not infringe any published and valid patent rights. EXCEPT FOR THE FOREGOING IN THIS SECTION 6.1, CMC ICOS
MAKES NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESS, STATUTORY OR IMPLIED, INCLUDING REGARDING THE SUBJECT MATTER OF ANY OF
THE CHEF1 TECHNOLOGY, PATENT RIGHTS, OR OTHERWISE, INCLUDING MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR THAT THE SAME
CAN BE USED TO DEVELOP, MAKE, HAVE MADE, USE, SELL, OFFER FOR SALE OR IMPORT LICENSEE PRODUCTS WITHOUT INFRINGING ANY INTELLECTUAL
PROPERTY RIGHTS OF A THIRD PARTY. CMC ICOS SHALL NOT BE LIABLE FOR LOSS OF PROFITS, LOSS OF USE, OR OTHER INDIRECT, INCIDENTAL,
CONSEQUENTIAL, PUNITIVE OR EXEMPLARY DAMAGES. Nothing contained herein shall be interpreted as derogating any representation, responsibility
or liability under the Master Services Agreement to which this Agreement is attached.

 

    - 7 -

     

    

 

 

 

6.2       Licensee
Representations and Warranties. Licensee represents and warrants that it: (a) has all necessary right and authority to
enter into and perform this Agreement; and (b) will comply and require that its Subcontractors and Sublicensees to comply
with all applicable laws, regulations and ordinances regarding this Agreement, Licensee Product, exercise of rights and/or
performing obligations hereunder, including relating to the use of the CHEF1 Technology. Licensee assumes all liability for
any losses, claims, demands and damages which may arise from the use, storage or disposal of the Materials.

 

7.            Confidentiality

 

7.1       Obligations.
Except as expressly provided herein, the parties agree that for the life of the Patent Rights and for 5 years thereafter, the Receiving
Party and only those of its Affiliates, directors, officers, counsel, employees, subcontractors and sublicensees who need to know
the same and who are under binding obligations of confidentiality and non-use in respect of the same, shall use Confidential Information
of Disclosing Party only in furtherance of the rights and obligations hereunder and shall treat the Confidential Information of
the Disclosing Party with the same degree of care it uses with respect to its most confidential information but in no event less
than a reasonable standard of care and shall not publish, otherwise disclose, use or transfer such Confidential Information of
Disclosing Party in whole or in part in contravention of the terms herein. The Receiving Party shall at all times be responsible
and liable to the Disclosing Party for any disclosure or use of the Disclosing Party’s Confidential Information by any of
the Receiving Party’s Affiliates, directors, officers, counsel, employees, subcontractors and sublicensees.

 

7.2       Terms
of the Agreement. The parties agree that the financial terms of this Agreement stated in Section 3 shall be treated as Confidential
Information and shall not be disclosed unless permitted in accordance with Section 7.3. Notwithstanding the aforesaid, either party
shall be entitled to disclose the contents and the existence of this Agreement in connection with a bona fide due diligence inquiry
under obligations of confidentiality.

 

7.3       Required
Disclosure. If a Receiving Party is required by law, regulation or court order to disclose any Confidential Information of
Disclosing Party, it shall: (a) notify the Disclosing Party promptly; (b) reasonably assist Disclosing Party to obtain a protective
order or other remedy of the Disclosing Party’s election; (c) furnish only that portion of the Confidential Information that
is legally required; (d) exercise reasonable efforts to obtain reliable assurance that the Confidential Information shall be held
in confidence; and (e) allow Disclosing Party prior review of such disclosure.

 

8.            Indemnification

 

8.1       Indemnification
of CMC ICOS.

 

(a) Licensee shall,
at all times during the Term of this Agreement and thereafter, indemnify, hold harmless, and defend CMC ICOS, its officers,
directors, employees, independent contractors, representatives and agents (“CMC ICOS Indemnitees”) from and
against all claims, losses, damages, and/or liability of whatsoever kind or nature, as well as all costs and expenses,
including legal expenses, reasonable attorneys’ fees and court costs, which arise or may arise at any time out of or in
connection with a breach by Licensee of this Agreement, any activity of Licensee and/or any Subcontractor and/or Sublicensee
exercising rights, performing or failing to perform, involving the research, development, manufacture, sale, offer for sale,
use or import of any one or more Licensee Product(s), and/or other act or omission of gross negligence or willful misconduct,
except to the extent such claims or suits are subject to the indemnification obligations of CMC ICOS pursuant to Section
8.2.

 

    - 8 -

     

    

 

 

 

(b) Upon the assertion
of any such claim or suit, the CMC ICOS Indemnitees shall promptly notify Licensee thereof, and shall permit Licensee to assume
the direction and control of the defense of the claim at its sole election (including the reasonable selection of counsel) and
the right to reasonably settle, at the sole discretion of Licensee, providing that such settlement does not impose any obligation
on or admission of fault by CMC ICOS Indemnitees, including compromising any of the Patent Rights and/or CHEF1 Technology, and
shall reasonably cooperate as requested (at the expense of Licensee) in the defense of the claim. Should Licensee cease to continue
to indemnity CMC ICOS Indemnities (whether in breach or otherwise) CMC ICOS shall have the right to assume direction and control
of the defense of the claim, the costs of which shall be subject to indemnification by the Licensee.

 

8.2          Indemnification
of Licensee.

 

(a)        CMC
ICOS shall, at all times during the Term of this Agreement and thereafter, indemnify, hold harmless and defend Licensee, its officers,
directors, employees, independent contractors, representatives and agents (“Licensee Indemnitees”) from and against
all claims, losses, damages, and/or liability of whatsoever kind or nature, as well as all costs and expenses, including legal
expenses, reasonable attorneys’ fees and court costs, which arise or may arise at any time out of or in connection with third
party claims or lawsuits against Licensee related to a breach by CMC ICOS of this Agreement or CMC ICOS’s gross negligence
or willful misconduct, except to the extent such claims or suits are subject to the indemnification obligations of Licensee pursuant
to Section 8.1.

 

(b)        Upon
the assertion of any such claim or suit, the Licensee Indemnitees shall promptly notify CMC ICOS thereof, and shall permit CMC
ICOS to assume direction and control of the defense of the claim at its sole election (including the reasonable selection of counsel)
and the right to reasonably settle it at the sole discretion of CMC ICOS provided that such settlement does not impose any obligation
on or admission of fault by Licensee Indemnitees, and shall reasonably cooperate as requested (at the expense of CMC ICOS) in the
defense of the claim.

 

8.3          Insurance.
The parties shall each carry liability insurance at their own expense adequate to ensure their respective compliance with their
obligations related to this Agreement. Licensee shall require its Sublicensees to comply with this requirement.

 

9.            Termination
and Expiration

 

9.1       Expiration.
This Agreement shall expire at the end of the Term of the Research License as defined in Section 1.13(a) or the Commercial License
as defined in Section 1.13(b), whichever is applicable. To the extent the expiration is in relation with the Commerical License,
then such license shall become non-exclusive, perpetual fully paid license to the CHEF1 Technology for Licensee Products.

 

    - 9 -

     

    

 

 

 

9.2       Termination
for Breach. If Licensee at any time defaults in any payment, fails to provide any report due hereunder, makes any false
report, or commits a material breach of any term or condition herein, CMC ICOS shall have the right at its sole discretion,
in addition to all other remedies, to terminate this Agreement in whole or in part and revoke any and all options and
licenses granted in whole or with respect to one or more Licensee Products by giving Licensee 30 days’ prior written
notice of such termination, provided that, if Licensee has rectified such default or breach within such 30-day period, then
this Agreement shall remain in effect and the rights and licenses herein granted shall remain in force as if Licensee had
committed no default or breach.

 

If CMC ICOS at any
time commits a material breach of any term or condition herein, Licensee shall have the right at its sole discretion, in addition
to all other remedies, to terminate this Agreement in whole or in part by giving Licensee 30 days’ prior written notice of
such termination, provided that, if CMC ICOS has rectified such breach within such 30-day period, then this Agreement shall remain
in effect and the rights and licenses herein granted shall remain in force as if CMC ICOS had committed no breach.

 

9.3       At-Will
Termination. Licensee shall have the right to terminate this Agreement with or without cause at any time on three (3) months’
prior notice by certified mail to CMC ICOS to be exercised no later than twelve (12) months prior to expiry of all Patent Rights
licensed hereunder. Thereafter, this Agreement may not be terminated at will.

 

9.4       Mutual
Termination. This Agreement will terminate immediately upon: (a) entry of an order for relief by or against a party under the
applicable bankruptcy code; (b) the making of a general assignment to the benefit of creditors; (c) the appointment of a general
receiver or trustee in bankruptcy of a party’s business or property; or (d) action by a party under any insolvency or similar
law for the purpose of its bankruptcy, reorganization, or liquidation.

 

9.5       Effect
of Termination or Expiration. Upon termination or expiration of this Agreement for any reason, nothing herein shall be construed
to release either party from any obligation accrued prior to the effective date of such termination or expiration, including relieving
Licensee of any payment obligations that have accrued prior thereto and the obligations of confidentiality and prohibition on use
set forth herein. Provisions of this Agreement which by their nature prescribe rights and obligations of the parties to be enjoyed
or performed after the expiration or termination of this Agreement shall survive until their purposes are fulfilled. Upon termination
of this Agreement for any reason the rights granted herein by CMC ICOS shall immediately revert to CMC ICOS and, at such time,
all Confidential Information received shall be returned or destroyed at the Disclosing Party’s election. Upon termination
but not expiration of this Agreement for any reason, Licensee shall, and shall procure its Sublicensees shall, cease all use of
CHEF1 Technology and Licensee Products. Licensee shall provide written notice to CMC ICOS that it has destroyed all physical vectors
and proprietary technology related to CHEF1 Technology.

  

10.          Assignment

 

Without the
prior written consent of the other party, either party may assign, delegate or otherwise transfer this Agreement only to an
assignee or transferee of its entire business or of all of that part of its business to which this Agreement relates
(including by way of merger, sale of shares or assets). Any assignment in contravention of the terms herein shall be null and
void. This Agreement shall be binding on and inure to the benefit of the parties and their permitted successors and assigns.
The representations, warranties, covenants, and undertakings contained in this Agreement are for the sole benefit of the
parties and their permitted successors and assigns and shall not be construed as conferring any rights on any other
party.

 

    - 10 -

     

    

  

 

 

11.          Non-Use
of Names

 

Neither party shall
use the names or trademarks of the other, nor any adaptation thereof, in any advertising, publicity, or the like without prior
written consent obtained from the other party in each separate case, except that the parties may state that Licensee is licensed
under one or more of the patents and/or applications within the Patent Rights.

  

12.          Export
Controls

 

It is understood
that CMC ICOS is subject to United States laws and regulations controlling the export of technical data, computer software, laboratory
prototypes, and other commodities that may require a license from the applicable agency of the United States Government and/or
may require written assurances by Licensee that Licensee will not export data or commodities to certain foreign countries without
prior approval of such agency. CMC ICOS neither represents that such license will be required nor that, if required, it will be
issued.

 

13.          Marking

 

Licensee shall mark
all Licensee Products with all applicable patent numbers under the Patent Rights so as to conform to the patent laws and practice
of all relevant countries regarding use, shipment, and/or sale of patented or patent-pending products.

 

14.          Miscellaneous
Provisions

 

14.1       Governing
Law. This Agreement shall be governed by the laws of England without regard to any choice-of-law provisions, except that questions
affecting the construction and effect of any patent shall be determined by the law of the country in which the patent was granted.
Any dispute, controversy or claim arising out of or in connection with this Agreement, its interpretation or performance hereunder
shall be settled exclusively by arbitration in accordance with the International Chamber of Commerce ("ICC") Arbitration
Rules as at present in force and shall be held at London, England in the English language by one arbitrator. The appointing authority
shall be the ICC acting in accordance with the Rules adopted by the ICC for this purpose. Notwithstanding the foregoing, the parties
hereby irrevocably consent and submit to the exclusive jurisdiction of the courts of England and waive any and all objections to
such court’s jurisdiction.

 

14.2       Entire
Agreement. This Agreement, including any Exhibit (which shall be incorporated herein by reference) as well as all
amendments made in accordance with this Section 14.2, (and the Confidentiality Agreement of October 20, 2010 between the
parties), sets forth the entire agreement and understanding of the parties as to the subject matter hereof and shall not be
amended or modified except by the execution of a written instrument executed by the parties. The failure of either party to
assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a
waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other party. To be
valid, a waiver must be made in writing and signed by the party so waiving. Each party acknowledges that it was provided an
opportunity to seek advice of counsel and, accordingly, this Agreement shall not be construed for or against either
party.

 

    - 11 -

     

    

 

 

 

14.3       Severability.
The provisions of this Agreement are severable and, if any provision of this Agreement shall be determined to be invalid or unenforceable
under any controlling body of law, such invalidity or unenforceability shall not in any way affect the validity or enforceability
of the remaining provisions hereof or the validity or enforceability of those terms in any jurisdiction where they are valid and
enforceable. The parties desire the terms herein to be valid and enforced to the maximum extent not prohibited by law, regulation
or court order in a given jurisdiction and as such, any invalid or unenforceable terms will be promptly reformed by the parties
to effectuate the intent of the parties as evidenced on the Effective Date.

 

14.4       No
Agency. Nothing contained in this Agreement shall be deemed to place the parties in a partnership, joint venture or agency
relationship and neither party will have the right or authority to obligate or bind the other party in any manner.

 

14.5       Headings
and Construction. The headings in this Agreement are for the convenience of the parties and shall not be interpreted as imparting
legal meaning. In this Agreement, references to “including” shall mean “including without limitation” and
 “terms” shall mean “terms and conditions”.

 

IN WITNESS WHEREOF,
the parties duly executed this binding agreement as of the Effective Date in one or more counterpart, each of which shall be deemed
an original but all of which taken together constitute one and the same instrument.

  

	ChemoMab Ltd.	 	CMC ICOS Biologics, Inc.  
	 	 	 
	By:	/s/ Adi Mor	 	By:	/s/ illegible signatory
	Name:	Adi Mor	 	Name:	Illegible
	Title:	CSO	 	Title	Illegible
	Date:	7/6/2015	 	Date:	7/6/2015

  

    - 12 -

     

    

  

 

EXHIBIT A

 

MATERIALS SPECIFICATIONS

  

    - 13 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]